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Abstract
Stem cells are characterized by a number of useful properties, including their ability to migrate, 
differentiate, and secrete a variety of therapeutic molecules such as immunomodulatory factors. As 
such, numerous pre-clinical and clinical studies have utilized stem cell-based therapies and 
demonstrated their tremendous potential for the treatment of various human diseases and 
disorders. Recently, efforts have focused on engineering stem cells in order to further enhance 
their innate abilities as well as to confer them with new functionalities, which can then be used in 
various biomedical applications. These engineered stem cells can take on a number of forms. For 
instance, engineered stem cells encompass the genetic modification of stem cells as well as the use 
of stem cells for gene delivery, nanoparticle loading and delivery, and even small molecule drug 
delivery. The present Review gives an in-depth account of the current status of engineered stem 
cells, including potential cell sources, the most common methods used to engineer stem cells, and 
the utilization of engineered stem cells in various biomedical applications, with a particular focus 
on tissue regeneration, the treatment of immunodeficiency diseases, and cancer.
1. Introduction
Cellular therapies are based on the direct injection of dissociated cells or tissues into patients 
and have shown great potential for use in biomedical applications. [1–3] This concept is not 
fundamentally new, as it has been more than half a century since cellular therapies were first 
introduced in the form of bone marrow (BM) and organ transplants. [4] However, recent 
breakthroughs in genetic engineering and gene/drug delivery are now allowing for safer and 
more precise cellular manipulation thereby improving the feasibility and potential 
applicability of cellular therapies in the clinic.
Correspondence to: Ki-Bum Lee.
In Memory of Professor Kahp-Yang Suh
HHS Public Access
Author manuscript
Adv Healthc Mater. Author manuscript; available in PMC 2018 February 13.
Published in final edited form as:
Adv Healthc Mater. 2016 January 07; 5(1): 10–55. doi:10.1002/adhm.201400842.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Currently, various cell types are being investigated including differentiated, undifferentiated 
progenitor, and stem cells, wherein each presents its own unique advantages and 
disadvantages. However, in general, the clinical application of differentiated cells is hindered 
by the practical difficulties that are associated with obtaining large cell populations, their 
lack of self-renewal capability, and poor engraftment upon transplantation. [5] Stem cells, on 
the other hand, can be distinguished from all other cell types by their unique ability to 
continuously self-renew and differentiate into intermediate and mature cells of a variety of 
lineages. In addition, they are relatively easy to isolate when compared to mature cells and 
exhibit the ability to migrate to sites of damage and disease in vivo. [6] Finally, stem cells 
can often contribute directly to therapy owing to their intrinsic secretion of therapeutic 
and/or beneficial factors such as anti-inflammatory cytokines or angiogenic factors. [7,8]
While the transplantation of unadulterated stem cells has shown great potential for the 
treatment of a variety of diseases and disorders, [3,9] recent efforts have increasingly focused 
on engineering stem cells to expand and control their innate functions. Specifically, the act 
of engineering stem cells can be defined as the modification of stem cells to control their 
behavior for a particular purpose (Figure 1). This encompasses the genetic modification of 
stem cells as well as the use of stem cells for gene delivery, nanoparticle delivery/loading, 
and even small molecule drug delivery. Currently, biomedical applications of engineered 
stem cells have primarily focused on regenerative medicine. In particular, studies have 
concentrated on engineering stem cells for the regeneration of cardiac, neural, and 
orthopedic tissues. [3,10] For instance, engineered neural stem cells (NSCs) can be 
transplanted following central nervous system (CNS) injuries such as spinal cord injury to 
promote neuronal cell survival and recovery or to guide NSC differentiation. Similarly, 
genetically modified stem cells are being developed for the treatment of more specialized 
genetic diseases including those related to immune deficiencies. [11] Finally, there has 
recently been increasing interest in engineering stem cells as potent cancer therapies, where 
stem cells can be used as the vehicle for gene therapy or for targeted chemotherapeutic 
delivery, owing to the demonstrated ability of stem cells to home to and infiltrate the tumor 
microenvironment. [12]
In this Review, we will briefly discuss the strategies that have been developed to engineer 
stem cells, followed by a comprehensive review of their biomedical applications, with a 
particular focus on tissue regeneration (e.g., neural, orthopedic, and cardiac tissue 
regeneration), the treatment of immunodeficiency diseases (e.g., muscle dystrophy, Wiskott-
Aldrich Syndrome, and leukodystrophies), and cancer. Specifically, we will highlight the 
astonishing progress that has been made over the last decade. While there are already a 
number of excellent reviews available that cover stem cell-based gene therapies, [3,10] this is 
a rapidly evolving area of research that is propelled by the constant expansion in our 
understanding of genetics and of methodologies and materials that can be used to engineer 
stem cells. Moreover, besides stem cell gene therapies, there have been limited reviews 
discussing other applications of engineered stem cell, such as their use as targeted drug 
and/or nanoparticle delivery vehicles. We hope that this article will inspire interest from 
various disciplines and highlight an exciting field wherein the use of our knowledge in 
genetic manipulation and nano/biotechnology to engineer stem cells can guide their behavior 
for use in various biomedical applications.
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2. Methods for Engineering Stem Cells
Owing to the rapid advancement in our understanding of genetics and cellular behaviors, 
there has been an equally expeditious development of techniques with which to specifically 
engineer stem cells in terms of gene modification as well as for the delivery of exogenous 
materials such as nanoparticles, drugs, and other factors. While there are already numerous 
excellent and more comprehensive reviews on these topics, [13] in this section, we seek to 
instill the background that the reader needs in order to fully appreciate and gain a deeper 
understanding of the biomedical applications in which engineered stem cells are being used. 
To this end, we will begin by giving a broad overview of the different stem cell sources that 
are currently available, focusing on the intrinsic advantages and disadvantages that each 
source holds for engineered stem cell applications. Lastly, we will highlight the methods that 
have been developed to engineer these stem cells including genetic modification of stem 
cells via viral and non-viral methods (e.g., lipids, polymers, and nanoparticles).
2.1. Stem Cell Source
There are currently a number of stem cell sources that are being investigated for use in 
biomedical applications, including adult stem cells, embryonic stem cells (ESCs), and 
induced pluripotent stem cells (iPSCs), where each has its own advantages and 
disadvantages. For example, adult stem cells are a readily available source that are free from 
ethical concerns, are less likely to form teratomas than other stem cell sources, and can be 
collected from the patient, modified, and then reintroduced into the patient. On the other 
hand, ESCs are pluripotent cells that can be extracted from the inner cell mass of early 
embryos. ESCs can give rise to almost all cell lineages and, as such, are the most promising 
cell source for regenerative medicine. However, there are ethical issues related to their 
isolation. As a result, the development of iPSCs, which share many properties with ESCs but 
without the associated ethical concerns, also shows great promise. Unfortunately, ESCs and 
iPSCs have both shown the potential for teratoma formation, thereby greatly compromising 
their current clinical utility.
In this subsection, we will focus on these stem cell sources (Table 1 ) with a discussion of 
their individual advantages and disadvantages and their current unadulterated use (e.g., 
without any modification) in cellular transplantation applications. For a more in-depth look 
at stem cell sources for biomedical applications, there are also various reviews available. 
[1,14–16]
2.1.1. Adult Stem Cells—Most of the biomedical applications that are discussed in this 
Review use adult stem cells. To understand the underlying reason, here, we will discuss the 
use of adult stem cells as a source for stem cell therapy in greater detail. Adult stem cells, 
also known as somatic stem cells, have been found in numerous tissues and are responsible 
for the maintenance and repair of the tissue in which they originate. Adult stem cell-based 
therapies have been successful for several decades, with the first hematopoietic stem cell 
(HSC) transplantation occurring over 50 years ago. [17] Adult stem cells are multi-potent and 
have the ability to differentiate into a number of lineages depending on their source tissue. 
For example, adult mesenchymal stem cells (MSCs) can readily differentiate into lineages of 
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the mesoderm including muscle, bone, tendons, cartilage, and fat. The three main sources of 
stem cells that will be discussed in this subsection include: 1) NSCs, 2) HSCs, and 3) MSCs.
2.1.1.1. Neural Stem Cells: NSCs, or neural stem/precursor cells (NSPCs), are a 
heterogeneous population of self-renewing multipotent cells that can be found in the 
developing and adult CNS. [16] NSCs were first identified in the rat brain in the 1960s as 
proliferating neural cells. [18] Since then, NSCs have been isolated from the embryo as well 
as from the adult CNS. In particular, NSCs can be collected from the ganglionic eminence of 
embryos as well as from both the subventricular zone (SVZ) of the lateral ventricles and the 
subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) in adults. [19] In terms of 
their differentiation, NSCs can differentiate into astrocytes, oligodendrocytes, as well as 
various types of neurons (e.g., dopaminergic). In vivo studies have demonstrated that 
transplanted NSCs can become incorporated into various brain regions, where they primarily 
differentiate into neurons and glia. [20] This lack of oligodendrocyte differentiation in vivo 
has been attributed to the low oligodendroglial differentiation efficiency of NSCs. [21] As 
such, NSCs represent a good source of stem cells for various biomedical applications, 
although concerns do exist owing to their limited availability and the difficult nature of their 
isolation.
Stem cell therapies using NSCs have primarily focused on the replacement of neurons for 
various nervous system disorders including Parkinson’s disease, Huntington’s disease, and 
spinal cord injury (SCI), which is currently being validated using numerous experimental 
models and a few clinical trials. [16] In terms of the experimental models, successes have 
been reported. However, a number of issues remain to be addressed including whether or not 
the transplanted NSCs can reach the target organ as well as whether, once at the target organ, 
the NSCs can differentiate into the appropriate lineage in sufficiently large numbers to give 
functional benefits. Moreover, our understanding of the in vivo differentiation process is still 
in its infancy. Though, it is clear that the disease microenvironment presents a complex 
combination of signals to the NSCs, which significantly differs from normal conditions, and, 
as such, may not be conducive to the survival and differentiation of NSCs into the intended 
lineage. [22] Furthermore, in the case of oligodendrocyte regeneration, NSC transplantation 
alone is unable to induce sufficient oligodendrocyte differentiation, which further confounds 
the use of NSCs for stem cell therapies. As such, there is significant room for investigation 
and improvement, which may be addressed using an engineered stem cell approach.
2.1.1.2. Hematopoietic Stem Cells: HSC transplantation is the most widely used stem cell 
therapy in the clinic today. It was originally developed for two purposes: 1) to treat 
individuals with inherited anemia or immune deficiencies by replacing the abnormal 
hematopoietic cells with cells from a healthy individual, and 2) to allow for the delivery of 
myeloablative doses of radiation and/or chemotherapy to cancer patients. [23] While 
effective, HSC transplantations come with a number of risks, with the most common being 
graft-versus-host disease (GVHD). [24]
There are three primary sources of HSCs: 1) BM, which is considered the classical source of 
HSCs, 2) peripheral blood, and 3) cord blood. The main differences between these sources 
are their reconstitutive and immunogenic potential. The first cell-surface marker that was 
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used to enrich for human HSCs was CD34, a ligand for L-selectin.[25] In particular, in vitro 
assays have revealed that almost all CD34+ cells have multi-potency or oligo-potency, but 
also that the population is very heterogeneous. In terms of the percentage of CD34+ cells 
that can be collected from the different cell sources, typically, the number of circulating 
CD34+ cells is held at a steady state of 0.06% while 1.1% of the cells in the BM are CD34+. 
As such, BM is the best source of HSCs and is the primary source used clinically. [26]
Besides the applications described above, HSC transplantation is being investigated for a 
number of disorders including immunological and genetic blood diseases. For instance, 
immunosuppression followed by the transplantation of CD34+ HSCs has recently been 
investigated in Phase I/II clinical trials for the treatment of multiple sclerosis in order to 
reconstitute the immune system following the removal of active autoreactive T cells. [27] 
Similarly, HSC transplantation has shown promise for rheumatoid arthritis as well as 
Crohn’s Disease. [28] Lastly, HSC therapies are in clinical trials for sickle cell disease, where 
it has been demonstrated that curative levels of T cell chimerism (>50%) using HLA-
matched sibling allogenic CD34+ HSC transplantations can be achieved. [29]
While HSC therapies have shown promising results in experimental models and in clinical 
trials, autologous HSC transplantation is not possible in every case, especially for genetic 
diseases. In addition, allogenic transplantation comes with significant risks of GVHD. As 
such, engineered HSCs may provide additional benefits such as genetically repairing 
autologous HSCs, which can then be transplanted to treat diseases such as Wiskott-Aldrich 
syndrome or muscular dystrophy as will be discussed in more detail later.
2.1.1.3. Mesenchymal Stem Cells: MSCs, which are also referred to as mesenchymal 
stromal cells, are a subset of non-hematopoietic adult stem cells that originate from the 
mesoderm. Like other adult stem cells, they possess self-renewal capabilities and can 
differentiate into multiple lineages. In particular, MSCs can not only differentiate into 
mesoderm lineages, such as chondrocytes, osteocytes and adipocytes, but also ectodermic 
cells (e.g., neuronal cells) and endodermic cells (e.g., pancreatic cells). [30] Importantly, 
MSCs exist in almost all tissues. For instance, they can be isolated from the BM, adipose 
tissue, the umbilical cord, liver, muscle, and lung.
To identify MSCs, there is a general consensus that human MSCs do not express the 
hematopoietic markers CD45, CD34, and CD14 or the co-stimulatory molecules CD80, 
CD86, and CD40. Instead, they express variable levels of CD105 (also known as endoglin), 
CD73 (ecto-5′-nucleotidase), CD44, CD90 (THY1), CD71 (transferrin receptor), the 
ganglioside GD2, and CD271 (low-affinity nerve growth factor receptor). Moreover, they are 
recognized by the monoclonal antibody STRO-1. In particular, it is thought that the observed 
variation in marker expression levels arise from differences in tissue source and culture 
conditions. [7]
As a result of the ease with which MSCs can be harvested as well as their multilineage 
differentiation capabilities, MSCs are currently the most widely used source for stem cell-
based research and therapy. Numerous clinical trials using MSCs alone (e.g., without genetic 
manipulation) have been performed, with the primary applications being tissue repair and 
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the therapy of immune disorders. In particular, MSCs have demonstrated reparative effects, 
where they are believed to be responsible for growth, wound healing, and the replacement of 
cells from everyday wear as well as from pathological conditions. [1] For instance, MSC 
transplantation has been shown to improve numerous musculoskeletal injuries and diseases 
including the regeneration of periodontal tissue defects, diabetic critical limb ischemia, bone 
damage caused by osteonecrosis, and burn-induced skin defects. [31] Besides 
musculoskeletal tissue repair, preclinical studies have also demonstrated that MSCs can 
effectively treat myocardial infarction as well as brain and spinal cord injuries. [32] On the 
other hand, MSCs also exhibit the capacity to regulate the immune response for the 
treatment of immune disorders. For example, MSC transplantation can reverse GVHD in 
patients receiving BM transplantation. [33] Similarly, the transplantation of both autologous 
and allogeneic MSCs was able to suppress inflammation and reduce damage to the kidneys 
and bowel in patients with Crohn’s disease. [34] It has also been reported that MSC 
transplantation can improve multiple sclerosis, amyotrophic lateral sclerosis, and stroke 
through their immunomodulatory effects. [35] Most importantly, MSCs for the treatment of 
GVHD and Crohn’s disease is currently the only stem cell-based drug approved by the FDA. 
[36]
 While already promising, similar to NSCs and HSCs, MSCs are great candidates for 
stem cell engineering, which can improve their survival and differentiation capacity thereby 
greatly enhancing the potential of MSCs for clinical applications.
Overall, adult stem cells are currently the most preferred cell type for downstream stem cell 
and engineered stem cell therapies as they are the most readily available and well 
established. Numerous studies and clinical trials have demonstrated that a large stem cell 
population can be obtained and expanded from patients (e.g., allogeneic source) and, 
following reintroduction into the patient, are less likely to form teratomas when compared to 
other stem cell sources upon long-term follow up. Finally, these cells are free from the 
ethical and moral issues associated with ESCs, which will be discussed in the following 
section.
2.1.2. Embryonic Stem Cells—The first successful isolation of human ESCs was 
achieved by Thomson and colleagues in 1998. [37] ESCs are pluripotent cells that are derived 
from the inner cell mass of developing blastocyst embryos and have the ability to 
differentiate to nearly all cell types. [38] Human ESCs are typically obtained from pre-
implantation or blastocyst-stage embryos that are created during in vitro fertilization 
procedures and can also be generated by somatic cell nuclear transfer or parthenogenetic 
activation of eggs. ESCs bring great potential in terms of understanding early human 
development, tissue formation, and differentiation into various cell lineages. However, the 
derivation of ESCs from the human embryo sparked controversy in the United States and led 
to a presidential executive order that restricted its government funding. [39] As a result of the 
limited numbers of stem cell lines that were approved for research, the diversity necessary to 
address some of the more compelling questions, such as those related to disease modeling 
and treatment was unmet. [40] In addition to the moral and ethical controversy surrounding 
the use of ESCs, ESCs also have other significant limitations. For instance, it has been 
shown that transplanted ESCs will form teratomas, and thus, ES cells must first be 
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predifferentiated ex vivo prior to grafting. [41] Lastly, as a nonautologous cell source, ESC 
transplantation faces the issue of immunological rejection. [22]
Despite these limitations, some ESC therapies are making their way into clinical trials. For 
instance, Geron conducted a Phase I clinical trial with oligodendrocyte precursor cells 
derived from ESCs for spinal cord injury. Advanced Cell Technology (ACT) also has Phase 
I/II approval for clinical trials on Stargardt’s Macular Dystrophy as well as dry macular 
degeneration. In these cases, they are deriving pigmented epithelial progenitor cells that can 
then be injected under the photoreceptor cells to redevelop and polarize the diseased retinal 
epithelium monolayer. As such, given the promising results that have been obtained from 
these preclinical and clinical studies as well as their immense differentiation potential, ESCs 
are also prime candidates for engineered stem cell applications. Albeit, further 
characterization and ESC sources, as well as a way to overcome the moral/ethical issues and 
teratoma formation that is associated with their use, will need to be addressed before ESCs 
become readily available for clinical applications.
2.1.3. Induced Pluripotent Stem Cells—While ESCs are a controversial source for 
pluripotent cells, iPSCs, which involve the reprogramming of adult cells towards an ESC-
like state, may be able to address the downsides of ESCs. In 2006, Takahashi and Yamanaka 
demonstrated that the exogenous expression of at least four transcription factors (Oct4, 
Sox2, Klf4, and c-Myc) was able to reprogram fibroblasts into ESC-like cells, which have 
been dubbed iPSCs. [42] iPSCs, like ESCs, can proliferate indefinitely while maintaining 
their potential to give rise to virtually all cell types. These cells are therefore rapidly 
becoming invaluable for regenerative medicine and biomedical research.
In theory, iPSCs should be pluripotent and, as such, should have the ability to generate cell 
types from each of the three embryonic germ layers: the endoderm, mesoderm, and 
ectoderm. However, there are key differences between iPSCs and ESCs. This is corroborated 
by the fact that iPSCs are generally less successful in generating high percentage chimeras 
and even less efficient in their ability to generate live mice in tetraploid complementation 
experiments when compared with ESCs. [43] While high quality iPSCs and ESCs do have 
identical transcriptional profiles, [44] in practice, iPSCs and ESCs harbor genetic and 
epigenetic differences that reflect their histories and could affect the application of iPSCs to 
clinical situations. Lastly, just like ESCs, iPSCs are able to develop teratomas and, in fact, 
previous studies have shown that iPSCs develop teratomas faster and more efficiently than 
ESCs regardless of the site of injection. [45] As such, iPSCs cells must also first be 
predifferentiated ex vivo prior to grafting.
Owing to the large number of unknowns that remain to be addressed in the use of iPSCs, 
most studies have only utilized iPSCs in vitro for disease modeling and drug screening. 
iPSCs as a source for cell therapies is also being investigated, but the majority of these 
studies are still in a preclinical stage. For instance, Hanna and co-workers used homologous 
recombination to repair the genetic defect in iPSCs derived from a humanized mouse model 
of sickle-cell anemia. [46] However, iPSCs are slowly making their way into the clinic, 
where in 2014, a Japanese patient was treated with iPSCs in order to treat macular 
degeneration. While long-term safety and efficacy of this treatment are not yet available, no 
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serious problems arose following surgery. As such, while limited engineered stem cell 
applications have utilized iPSCs, it can be argued that this stem cell source possesses the 
greatest potential, as they are pluripotent and can be derived from the patients’ own cells. As 
such, with continued optimization and investigation, we can expect to see an exponential rise 
in the use of iPSCs for stem cell and engineered stem cell therapies in the future. [14]
2.2. Genetically Engineering Stem Cells
The development of recombinant DNA technology in the 1970s marked the beginning of an 
exciting new era for biology. Molecular biologists gained the ability to manipulate DNA 
molecules, making it possible to study genes and harness them for the development of novel 
medicines and biotechnologies, which include engineering stem cells. However, to achieve 
the desired effects in engineered stem cells, the therapeutic genes must be carried by safe 
and effective vectors that can not only deliver genes specifically to the target cells but also 
sustain their expression thereafter. Other properties that these vectors should possess 
include: 1) high transfection efficiency, 2) long-term stability without integration into the 
host genome, 3) ability to spatiotemporally express appropriate levels of the therapeutic 
gene, and 4) not stimulate the host’s immune system or induce cellular transformation. [47]
For this purpose, both viral and non-viral vectors have been developed. Non-viral vectors, 
such as lipid-based and polymer-based vectors as well as other nanoparticles, have the 
advantage of being nonpathogenic and having high loading capacities but are generally 
associated with low transfection efficiencies. On the other hand, viral vectors such as 
retroviruses, lentiviruses, adenoviruses, and adenovirus-associated vectors are much more 
efficient, resulting in numerous preclinical and clinical gene therapy studies. Viral vectors 
differ in their immunogenicity, packaging capacity, ability to transduce dividing and 
nondividing cells, ability to insert into the host genome, and their ease of manufacturing 
(Table 2).[48] However, serious issues arise with their biosafety. As such, careful 
consideration must be taken when deciding which vectors to use for engineered stem cell 
applications. In this section, we will cover the techniques that have been most commonly 
used to genetically engineer stem cells with particular focus on viral and non-viral gene 
delivery methods.
2.2.1. Viral Gene Therapy—Currently, the most efficient and common method of 
introducing genes into stem cells is by means of viral vectors. However, the chief concerns 
associated with this approach involve frequent transgene silencing and the fact that 
integration of the transgene into the host genome can activate nearby oncogenes, leading to 
the selection of subclones with abnormal growth behaviors. [49] Moreover, viral vectors are 
severely hampered by their immunogenicity. While a number of excellent reviews covering 
the progress and challenges faced by viral vectors for gene therapy are available, [50–52] in 
this section, we will briefly highlight the various viral vectors that have been applied to 
engineer stem cells. Specifically, we will focus on: 1) retroviral, 2) lentiviral, 3) adenoviral, 
and 4) adeno-associated viral vectors.
2.2.1.1. Retroviral Vector: Retroviral vectors were the first class of viral vector to be 
developed and have, historically, been the most widely used in clinical trials. [51] 
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Specifically, they are single-stranded RNA viruses that replicate in the host cell through 
reverse transcription, thereby producing DNA from its RNA genome. [53] Moreover, 
retroviruses have the ability to integrate into the host genome via an integrase enzyme. [54] 
However, it has been found that retroviral vectors are produced at relatively low titers, 
require proviral integration into the host chromosome for transduction, and can usually only 
infect dividing cells. As a result, these properties restrict most retroviral vector applications 
to ex vivo gene transfer approaches, which is not necessarily a significant limitation for the 
purpose of engineering stem cells.
For the purpose of engineering stem cells, retroviral vectors have traditionally been the 
vector of choice for the ex vivo transduction of HSCs and they offer two main advantages. 
First, they are non-immunogenic in nature. Second, and more importantly, they can offer 
constitutive transgene expression owing to their ability to integrate into the host genome. As 
a result, the genetically engineered stem cells can be used to treat various diseases. On the 
other hand, retroviral vectors are hampered by a number of significant limitations. 
Specifically, the use of retroviral vectors results in arbitrary integration of the inserted DNA 
into the host genome. This could modulate endogenous gene expression via insertional 
mutagenesis of a proto-oncogene or tumor suppressor resulting in carcinogenesis of the 
engineered stem cells. [51] As a result, in recent years, there has been a decline in the use of 
retroviral vectors for clinical trials (currently, only 19.7% of trials used retroviral vectors 
compared to 28% and 22.8% in 2004 and 2007, respectively). [52]
2.2.1.2. Lentiviral Vectors: Lentiviral vectors, such as the human immunodeficiency virus 
(HIV), are specialized members of the retroviral family. Like retroviral vectors, lentiviral 
vectors can integrate into the genome of the host cell. However, unlike other retroviruses, 
lentiviral vectors have the advantage of being able to transduce non-dividing cells. As such, 
these vectors are one of the most efficient viral methods for gene delivery.
In terms of engineering stem cells, one of the key rationales for using lentiviral vectors is 
their ability to transduce stem cells with a high efficiency after only a short ex vivo infection, 
which can favor the maintenance of stem cell properties. For example, this has been 
demonsrated in HSCs. [55] Moreover, lentiviruses are known to be less genotoxic than other 
retroviral vectors. [56] However, the potential for carcinogenesis, as induced by insertional 
mutation, is still a major hurdle for the clinical application of lentiviral vectors. For instance, 
a clinical trial using a lentiviral vector expressing β-globin to transduce hematopoietic 
progenitor cells was conducted for the treatment of a patient with β-thalassaemia-based 
anemia. [57] In this patient, following engineered stem cell transplantation, 10% of the 
erythroid cells contained the vector, but in 3% of cells the vector had integrated into the high 
mobility group AT-hook 2 (HMGA2) gene, which has previously been linked to cellular de-
differentiation and metastasis of solid tumors. [58] Fortunately, at 33 months, this patient had 
no evidence of malignancy. Lastly, besides the potential for carcinogenesis, stem cells 
display low permissivity to the vector, thereby potentially requiring cytokine stimulation in 
order to increase transduction efficiency. [55]
2.2.1.3. Adenoviral Vectors: Adenoviral vectors are non-enveloped icosahedral viruses that 
are composed of a nucleocapsid and a double-stranded linear DNA genome. [59] Adenoviral 
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vectors have a number of advantages, which make them attractive for stem cell engineering. 
Specifically, the 36 kb genome of the adenoviral vector provides ample space for the 
insertion of large sequences. [50] Moreover, adenoviral vectors have high transduction 
efficiency in both dividing and nondividing cells allowing for the collection of high titers 
with relative ease. Finally, the vector remains episomal and, as such, does not integrate into 
the host genome. As a result, the number of clinical trials using adenoviral vectors is 
growing with 23.3% of clinical trials using adenoviral vectors as of 2012. [52]
For stem cell applications, these properties may be particularly useful as the transient 
expression of the transduced gene can help prevent overgrowth of the transplanted stem cells 
(e.g., for tissue regeneration). However, there are also significant barriers that adenoviral 
vectors must first overcome before they can be useful in the clinic. For example, they are 
limited by their large size as well as their great immunogenicity. [60] Moreover, although 
recombinant adenoviral vectors were the first to result in high levels of systemic gene 
transfer in mammals, when delivered systemically they can induce severe toxicity at the 
dosage levels that are required for efficacy, especially in humans. To address this, second- 
and third-generation vectors contain additional deletions of the viral genes thereby reducing 
toxicities. However, even when all of the viral genes are deleted using a helper-dependent 
packaging system, [61] the vectors are not completely devoid of toxicity and transduction 
with these vectors can result in large changes in endogenous gene expression profiles. [62]
2.2.1.4. Adeno-Associated Viral Vectors: Adeno-associated viral vectors are derived from 
the parvovirus family and are small viruses with a single-stranded DNA genome that 
requires a helper virus for replication and completion of their life cycle. [63] When compared 
to adenoviral and other viral vectors, adeno-associated vectors are characterized by a number 
of advantages such as the ability to infect both dividing and non-dividing cells. In addition, 
the vector is largely episomal (>99%) and the <1% that is not, predictably integrates into 
human chromosome 19. [64] Finally, it is not currently related to any human disease and it 
has a lower immunogenicity.
As a result of these properties, adeno-associated viral vectors are currently the vector of 
choice for clinical viral transduction (4.9% in 2012, which continues to grow). [52] Previous 
studies have demonstrated that these vectors can mediate 10 to 100-fold higher levels of 
transgene expression both in vitro and in vivo compared to other vectors. However, because 
of their small size (2.4–4 kb), they can only accommodate small genes thereby limiting their 
therapeutic usefulness. [65,66] Moreover, despite their lower immunogenicity, one study 
reported the formation of hepatocellular carcinoma as a result of adeno-associated viral 
vector integration near a miRNA locus that is known to be involved in tumorigenesis. [67] On 
the other hand, and more significantly, a clinical trial conducted by Nathwani and colleagues 
demonstrated that adenovirus-associated viral vector-mediated gene transfer in Hemophilia 
B did not result in any acute or long-lasting toxicity but follow-up with a larger number of 
patients and for longer periods of time is necessary before a full evaluation of the usefulness 
of adeno-associated viral vectors can be made. [68]
In stem cells, studies have demonstrated that adeno-associated viruses can be used to 
transduce stem cells that originate from the muscle and brain. [69] However, the efficiency is 
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significantly reduced when compared to the transduction of mature cells. For example, in 
muscle, Arnet et al. found that adeno-associated viral vectors were able to transduce 
proliferating myoblasts in culture with reduced efficiency relative to postmitotic myocytes 
and myotubes. [70] In addition, quiescent satellite cells were refractory to transduction in 
vivo in adult mice. On the other hand, for HSCs, some investigators have claimed that HSCs 
were impervious to adeno-associated viral transduction while others have reported that these 
vectors were capable of transducing HSCs but only at high vector-to-cell ratios. [69] Either 
way, despite their low transduction efficiency, recent efforts have focused on using directed 
evolution to enhance the utility of adeno-associated viruses for stem cell applications. To 
this end, Asuri and co-workers generated an adeno-associated virus variant with high gene 
delivery efficiencies (≈50%) to human pluripotent stem cells and a considerable increase in 
gene-targeting frequencies (up to 0.12%). [71]
2.2.2. Non-Viral Delivery Vehicles—Several limitations of viral vectors, such as safety 
concerns that include carcinogenesis, immunogenicity, broad tropism, as well as their 
relatively small capacity for therapeutic DNA, have prompted the development of synthetic 
non-viral vectors. [72] The ideal non-viral vector should be able to overcome the many 
barriers involved with systemic delivery, including: 1) targeted delivery, 2) efficient cell 
uptake and endosomal escape, and 3) the release of its cargo, all in a biocompatible manner 
while protecting the cargo from degradation. To this end, nanoparticles can provide a 
promising platform for gene delivery to stem cells.
Nanoparticles offer a number of advantages over viral vectors, including: 1) a lower 
immunogenicity, 2) the ability to deliver larger payloads, and 3) generally being easier to 
prepare/synthesize. [73,74] In addition, nanoparticles can be used to deliver other nucleic 
acids (DNA, RNA), biomolecules (e.g., peptides, proteins), small molecule drugs, and can 
also provide additional multifunctionalities (e.g., heating, imaging). [75] Owing to their great 
potential, a plethora of nanoparticle systems have been developed to overcome the 
physiological barriers faced by non-viral delivery methods. Specifically, these nanoparticles 
can be composed of various materials including metals, noble metals, semiconductors, 
polymers, lipids, and other inorganic materials and can have various sizes, shapes, and 
properties. [76] However, few of these vectors have made it through clinical trials to become 
FDA approved. [72] In addition, they are generally hampered by lower delivery efficiencies 
relative to viral vectors. [77] As such, while these vehicles possess great potential, there is 
still significant room for improvement before they can be widely used in the clinic. In this 
section, we will give a brief overview of some of the most common nanoparticle systems 
that have been developed for engineering stem cells with particular focus on lipid- and 
polymer-based vectors as well as gold and magnetic nanoparticles.
2.2.2.1. Lipid-Based Vectors: Currently, the most widely used non-viral delivery vehicle 
consists of lipid-based vectors. Lipid-based vectors are generally characterized of by three 
components: a cationic head group, a hydrophobic tail, and a linker group. [74] The 
liposomal delivery of DNA was first demonstrated in 1980, wherein the phospholipid 
phosphatidylserine was used to deliver SV40 DNA to monkey kidney cells. [78] Since then, 
numerous lipid-based vectors with more efficient transfection properties have been 
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developed. Synthetic cationic lipids such as DOTMA, DOSPA, DOTAP, DMRIE and DC-
cholesterol spontaneously form small, uniform liposomes that are capable of efficient 
encapsulation and delivery of DNA to various mammalian cells including stem cells. 
[72,74,79]
 On the other hand, neutral lipids, such as the fusogenic phospholipid DOPE or the 
membrane component cholesterol, have also been utilized as a component of liposomal 
formulations to enhance transfection activity and nanoparticle stability. [80] However, despite 
being the most widely used non-viral delivery vehicle, limitations do exist, including low 
efficacy owing to poor stability and rapid clearance, [81] as well as the generation of 
inflammatory or anti-inflammatory responses. [82]
2.2.2.2. Polymer-Based Vectors: An alternative class of non-viral vectors consists of 
cationic polymers, which are attractive owing to their immense chemical diversity and the 
relative ease with which they can be functionalized. The most widely developed examples of 
polymeric vectors include poly(l-lysine) (PLL) and polyethylenimine (PEI), which have both 
been demonstrated to efficiently transfect stem cells. [72] Besides PLL and PEI, a number of 
other polymers, which have shown efficacy for stem cell transfection, are also available. For 
instance, PLGA is a popular choice and can be used to create nanoparticles via solvent 
evaporation. Finally, chitosan is another popular polymer with an intrinsically positive 
charge.
In particular, PLL is a homopolypeptide of the basic amino acid lysine although unmodified 
PLL shows marked in vitro cytotoxicity. [83] Moreover, in the absence of a lysosomal 
disruption agent such as chloroquine, PLL has fairly poor transfection ability. [74] As a 
result, numerous copolymer variants of PLL with enhanced gene delivery properties have 
been reported. [84] One example includes PLL coated with the hydrophilic polymer 
polyethylene glycol (PEG), which is designed to minimize nonspecific interaction with 
serum components and thereby increase circulation time. [85] On the other hand, PEI and its 
variants are among the most studied polymeric materials for gene delivery. PEI is a polymer 
that has a high positive charge density, especially at reduced pH values, owing to the 
existence of a nitrogen atom at every third position along the polymer. As a result, it has 
been hypothesized that this can aid in the condensation of DNA as well as enhance 
endosomal escape. [86] In terms of its transfection efficiency as well as its cytotoxicity, this 
strongly depends on the structural properties of PEI such as molecular weight and whether it 
is in a linear or branched form. [87] As with PLL, owing to the cytotoxicity of PEI, a range of 
modifications have been investigated including block co-polymers of PEG and PEI for 
improved stability and biocompatibility, degradable disulphide-crosslinked PEIs for reduced 
toxicity, and alkylated PEI to increase transfection ability. [72]
2.2.2.3. Gold Nanoparticles: Gold nanoparticles (GNPs) are one of the most widely used 
nanoparticles for stem cell applications. In particular, GNPs are attractive owing to their 
amenability to synthesis and functionalization. Moreover, they are very inert and non-toxic. 
Specifically, numerous studies have demonstrated that GNPs are well tolerated by stem cells 
depending on how they are coated and can be used to guide stem cell differentiation by 
delivering nucleic acids, other biomolecules, and/ or small molecule drugs. [88]
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GNPs have been synthesized using an array of methods, which are mainly based on the 
reduction of chloroauric acid in the presence of a stabilizing agent. For example, the most 
commonly used method is the citrate synthesis method, which involves reduction of 
chloroauric acid using trisodium citrate thereby resulting into the formation of GNPs. The 
size of the obtained GNPs is determined mainly by the salt concentration, temperature and 
rate of addition of reactants resulting in a typical size range of 10–25 nm. However, a range 
of 1–100 nm or more can also be achieved by varying the salt concentration and 
temperature. [89] To utilize GNPs for drug or gene delivery, a number of functionalization 
have been investigated. In particular, as mentioned previously, the surface of GNPs can 
readily be modified using thiol-based chemistry. As such, GNPs have been stabilized via 
citrate as well as the more bioapplicable PEG. In addition, to allow for gene or drug delivery 
to stem cells, GNPs can be covalently modified with the gene or drug. Alternatively, non-
covalent methods such as electrostatic interaction between PEI and nucleic acids can also be 
used and has been demonstrated successfully in stem cells. [90]
2.2.2.4. Magnetic Nanoparticles: Lastly, there has been considerable interest in magnetic 
nanoparticles (MNPs) as multifunctional nanoplatforms for stem cell applications. In 
particular, MNPs have many unique properties such as high biocompatibility, facile surface 
modification, and magnetic properties that result in an intrinsic ability to enhance MRI 
contrast, induce hyperthermia, [91] and be used for magnetic targeting. [92] As a result, it has 
been demonstrated that MNPs are biocompatible with stem cells and can actually enhance 
transfection efficiency via magnetically facilitated transfection (e.g., magnetofection). [93]
MNPs, such as the most common Fe3O4 MNPs, are typically synthesized through the co-
precipitation of Fe 2+ and Fe 3+ ions in basic aqueous media or thermal decomposition, 
which results in more uniform and highly crystalline structures. [94] In addition, it has been 
found that doping MNPs with other metals such as Zn 2+ or Mn 2+ can greatly enhance the 
magnetization of the resulting MNPs, which is critical for downstream applications (4- to 
14-fold increase in MRI contrast, which can be used to monitor stem cell migration, and 4-
fold enhancement in hyperthermic effects for the treatment of cancer). [95] Generally, as with 
GNPs, these MNPs are coated with biocompatible polymers, such as dextran, dextran 
derivatives, or PEG, to confer stability in a biological system. In addition, nucleic acids, 
biomolecules, and small molecule drugs can be conjugated via covalent or non-covalent 
bonds (e.g., PEI via electrostatic interaction). As a result of their great potential, many MNP 
formulations are under clinical investigation and some formulations are already FDA 
approved with MRI contrast being their primary area of application. Finally, investigations 
have recently focused on the development of magnetic core-shell nanoparticles (MCNPs) 
wherein the MNP is coated with a shell that provides additional functionalities such as gold 
or mesoporous silica (e.g., dark-field imaging and increased drug loading, respectively). [96] 
As a result, MNPs and MCNPs have particularly great potential for stem cell engineering 
owing to their multifunctionalites and tunability.
3. Engineering Stem Cells for Tissue Regeneration
Regenerative medicine focuses on differentiating stem cells along specific lineages to 
effectively repair damaged or failing organs/tissues. [97] To achieve this goal, numerous 
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strategies have been devised including the direct transplantation of various stem cells from 
different sources, the use of substrates, as well as engineering stem cells via genetic 
modification. In this Section, we will give a comprehensive review of the use of engineered 
stem cells for the regeneration of various tissues including the central nervous system 
(CNS), muscle, cartilage, and the heart.
3.1. Engineering Stem Cells for Neurological Diseases
As mentioned previously, the goal of cell therapy for neurological diseases is to replace and 
support neurons in diseased tissue. Stem cells, such as NSCs, have shown great potential for 
this purpose wherein stem cell transplantation can allay inflammation and replace tissues 
thereby resulting in functional benefits. However, the specific differentiation of NSCs to 
desired lineages (e.g., neurons and oligodendrocytes) is confounded by the 
microenvironment of neurological diseases and disorders. As a result, to enhance the 
efficacy of stem cell therapies, engineered stem cells, wherein the stem cells are modified to 
specifically secrete and deliver molecules that can further guide differentiation or 
revascularization, could greatly improve the potential of stem cell therapies for neurological 
diseases. In this section, we will primarily focus on the use of engineered stem cells to 
improve stem cell-based therapies for spinal cord injury, Alzheimer’s disease, Parkinson’s 
disease, and stroke.
3.1.1. Spinal Cord Injury—Spinal cord injury (SCI), which affects roughly 10 to 40 out 
of every million people in developed countries, [98] is a severely debilitating event that often 
results in permanent neurologic deficits, including partial to total sensorimotor loss, the 
disruption of autonomic nervous system control caudal to the injury, and chronic pain. The 
pathophysiology of SCI is divided into two phases: a primary and a secondary injury. The 
primary injury consists of the initial insult, which results in either contusion (e.g., caused by 
shattered vertebral bones) or compression (e.g., caused by an increased pressure) of the 
victim’s spinal cord. [99] Following the initial insult, a secondary injury ensues, which 
occurs on a cellular level. This phase begins with massive cell death due to immune response 
to the injury and is followed by secondary necrosis and apoptosis as well as oxidative, 
excitotoxicity, and axonal damage. As a result of the extensive neuronal death, axonal 
demyelination, as well as the limited ability of the mammalian central nervous system 
(CNS) to repair itself and replace lost cells, signal transduction through the spinal cord is 
compromised leading to the observed SCI-related functional impairments. While some 
treatments exist for SCI, they can only improve neurologic recovery by minimizing the 
secondary injury if administered promptly after SCI [100] and, as such, there are currently no 
cures. Therefore, cell replacement therapies represent a potential strategy that can overcome 
the loss of neurons and oligodendrocytes while providing neural protection thereby bridging 
the lesion site and creating an environment in which remyelination, axon elongation, and the 
formation of new circuits may occur.
For this purpose, stem cells hold great potential. Numerous studies have indicated that the 
grafting of NSCs into rodents following the induction of SCI can produce axonal regrowth 
and functional recovery. [101] As a result of these promising experimental results, a number 
of human clinical trials involving NSCs from various sources are now being conducted for 
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the treatment of SCI. [102] For example, in December 2010, Stem Cells Inc. initiated a Phase 
I/II clinical trial utilizing human NSCs generated from the brain of an aborted human fetus 
to treat patients who sustained a thoracic SCI. While data has not yet been reported, a 
previous phase I clinical trial by Stem Cell Inc. using the same NSCs for Pelizaeus-
Merzbacher disease, a rare leukodystrophy, demonstrated that the transplantation procedure 
was safe and resulted in modest improvements in cognitive function in three of the four 
patients enrolled. [103]
While the outcome of NSC transplantation for SCI appears promising, the mechanisms 
underlying these functional improvements have not been completely elucidated. [102] For 
instance, Hofstetter et al. reported that although the transplantation of naïve NSCs improved 
motor function, it also caused aberrant host fiber sprouting, which has been associated with 
allodynia-like hypersensitivity in a rodent model of SCI. [104] This suggests that the 
controlled differentiation of transplanted stem cells is essential in order to avoid possibly 
serious side effects and to achieve optimal functional improvements. In particular, 
engineering stem cells for the treatment of SCI can provide the benefits of stem cell 
transplantation while allowing for specific control over cellular behaviors such as guided 
differentiation or the secretion of therapeutic molecules via genetic modification. To this 
end, the two main strategies that have been investigated include engineering stem cells to 
secrete neurotrophins, which promotes neurite outgrowth and proliferation, or engineering 
them to secrete other factors that can specifically guide the differentiation of the transplanted 
stem cells.
3.1.1.1. Secretion of Neurotrophins: One commonly utilized genetic modification for the 
treatment of SCI is to engineer stem cells to secrete neurotrophins. Neurotrophins, such as 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), 
and ciliary-derived neurotrophic factor (CNTF), are a family of growth factors that can 
positively modulate the survival, development, and function of neurons. Previous studies 
have demonstrated that neurotrophins primary act through the Ras/MAPK and PI3K/Akt 
signaling pathways via the activation of Trk receptors. [105] Specifically, when used in the 
context of SCI, the introduction of neurotrophic factors into the site of injury has been 
shown to increase the extent of axonal growth thereby increasing both the length and density 
of projections as well as subsequent improvements in locomotor function. [106]
The earliest examples of engineering cells with a neutrophin for SCI utilized fibroblasts as a 
cell source. Grill and colleagues demonstrated that primary skin fibroblasts engineered to 
secrete NT-3, a neurotrophin that has previously been demonstrated to support the survival 
and differentiation of neurons as well as the formation of new synapses, [107] could enhance 
corticospinal tract regeneration and locomotion recovery following transplantation into SCI 
lesions. [108] While the transplantation of engineered fibroblasts that overexpress NT-3 could 
support and protect surviving neurons, thereby inducing some locomotor recovery, 
fibroblasts are unable to replace neurons and oligodendrocytes, which is a critical side effect 
of SCI that needs to be addressed. As such, Zhang and co-workers advanced the field by 
engineering NSCs (C17.2) [109] to express NT-3 neurotrophin. [110] Previous studies have 
already demonstrated that C17.2 NSCs constitutively secrete neurotrophic factors including 
NT-3, and in fact, can elicit a response from a wider range of host axons then engineered 
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fibroblasts. [111] However, Zhang et al. demonstrated that engineering NSCs to secrete 
higher levels of NT-3, via introduction of a plasmid vector, could bring additional 
therapeutic benefits including enhanced cell survival and proliferation (of both transplanted 
NSCs and surviving neurons) over unengineered NSCs alone. Moreover, transplantation of 
these engineered NSCs not only promoted cellular survival and proliferation but, upon 
transplantation, also demonstrated an enhancement in functional recovery (via Basso, 
Beatie, and Bresnahan scoring) owing to the increase in axonal density.
Recently, Kumagai and colleagues demonstrated that they could engineer other stem cell 
types for the treatment of SCI. In this case, they used a lentiviral vector to engineer MSCs to 
secrete the neurotrophin MNTS1, which binds to TrkA, TrkB, and TrkC, and p75 NTR.[112] 
In their study, engineered MSCs and control MSCs were transplanted seven days after SCI 
(via contusion) in rats and it was found that MSCs engineered to secrete MNTS1, but not 
control MSCs, were able to enhance axonal growth and significantly prevent cutaneous 
hypersensitivity following injury (Figure 2). In addition, the transplantation of engineered 
MSCs was able to promote angiogenesis and a modification of the glial scar was observed. 
This demonstrates the potential of MSC transplantation along with NSCs for the treatment 
of SCI.
3.1.1.2. Guided Differentiation: While neurotrophic factors can enhance neurite outgrowth 
and proliferation, NSCs that are transplanted into the spinal cord typically differentiate into 
astrocytes, which can actually hinder the effectiveness of NSC transplantation. [113] NSCs 
that have been engineered to express neurotrophic factors are no different. As such, another 
method that has been investigated to improve NSC-based SCI treatments is to engineer 
NSCs in order to control their differentiation following transplantation. To this end, a 
number of studies have sought to guide the differentiation of transplanted NSCs toward an 
oligodendrocyte lineage. Typically in the CNS, oligodendrocytes are responsible for the 
formation of the myelin sheath that surrounds axons, which, in turn, supports the fast 
saltatory conduction of nerve impulses in the nervous system. [114] However, the widespread 
apoptosis of oligodendrocytes that is typically observed following SCI has been found to be 
a major factor associated with the observed functional deficits, including impairment in the 
effective transmission of nerve impulses. [115] To address this deficit, Hwang and co-workers 
engineered NSCs to overexpress the Olig2 gene via retroviral transduction. [116] Olig is a 
family of transcription factors that are key regulators of differentiation along the 
oligodendrocyte lineage during development. [117] In particular, Olig2, a member of the Olig 
family, is more highly expressed in the spinal cord during early developmental and may play 
a crucial role in the differentiation of oligodendrocytes in the spinal cord. [118] As such, by 
overexpressing Olig2, Hwang et al. not only demonstrated that the engineered NSCs could 
differentiate exclusively into the oligodendrocyte lineage in vitro but also that the in vivo 
transplantation of these engineered NSCs improved locomotor function and increased the 
degree of myelination following SCI in a rodent model.
To further enhance the differentiation of NSCs to oligodendrocytes, Hu and colleagues 
recently demonstrated that the combination of engineered NSCs overexpressing Olig2 along 
with myelin basic protein-activated T (MBP-T) cells could synergistically improve the 
survival of transplanted NSCs thereby greatly enhancing the therapeutic outcome. [119] In 
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this case, MBP-T cells were passively immunized for the purpose of modifying the SCI 
microenvironment in order to facilitate oligodendrocyte differentiation. [119] Previous work 
from their group had already demonstrated that T cell-based vaccination of mice with MBP, 
when combined with the transplantation of NSCs into the cerebrospinal fluid, synergistically 
promoted functional recovery following SCI. [120] The introduced MBP-T cells were then 
able to infiltrate the injured spinal cord thereby modulating the local T cell and microglial 
response. More importantly, this induced an increase in brain-derived neurotrophic factor as 
well as the differentiation of resident microglia and infiltrating blood monocytes into 
“alternatively activated” anti-inflammatory macrophages. As a result, newly formed neurons 
were observed from the endogenous NSC pool, substantiating the contention that immune 
response plays a crucial role in the recruitment of NSCs to the lesion site. As such, they 
hypothesized that similar immunological manipulations with MBP could also serve as a 
means to facilitate the differentiation of NSCs specifically towards an oligodendrocyte 
lineage. From the combination of MBP-T cells and lentiviral-mediated Olig2-engineered 
NSCs, the authors reported that five times as many transplanted NSCs cells survived and, 
moreover, that the number of engineered NSCs that differentiated towards an 
oligodendrocyte lineage was over 12-fold more than unengineered NSCs, thereby 
significantly increasing the number of remylinated axons. Finally, a decrease in spinal cord 
lesion size and an increase in myelin were observed suggesting that there was a synergistic 
effect in transplanting engineered stem cells and modulating the immune cells following 
SCI.
3.1.2. Alzheimer’s Disease—Alzheimer’s disease (AD) is the leading cause of age-
related dementia, afflicting one in every eight people over the age of 65. It is characterized 
by a progressive loss of memory and other cognitive functions, often leading to the 
premature death of the patient. The hallmark pathological features of AD include the 
accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs). In addition, 
AD patients exhibit inflammation as well as widespread synaptic and neuronal loss. 
Typically, these Aβ plaques are a result of the extracellular accumulation of insoluble 
aggregates composed of the Aβ peptide, which induces neuronal cytotoxicity. On the other 
hand, NFTs consist of intraneuronal insoluble aggregates of tau, a micro-tubule binding 
protein. As a consequence of these Aβ plaques and NFTs, the nerve cells in the brain of AD 
patients progressively shrink and die, resulting in the gradual impairment of the patient’s 
memory and cognitive performance. [121]
Recently, a number of research groups have demonstrated that the transplantation of NSCs 
can markedly improve cognitive function, synaptic connectivity, and neuronal survival in 
experimental models of AD. [122,123] Importantly, however, it appears that the therapeutic 
effects of NSC transplantation are not mediated by the alteration of either Aβ or NFTs. 
Instead, the beneficial effects of NSC transplantation appear to be mediated by stem cell-
derived neurotrophins or other neuroprotective molecules. For instance, NSC-derived cells 
have been observed to elevate hippocampal levels of brain-derived neurotrophic factor 
(BDNF), leading to an increase in synaptic density and the restoration of cognitive functions 
in preclinical models of AD. [122] MSCs have also been found to improve cognition in AD 
models by modulating cytokine levels and ameliorating brain inflammation. [5] Thus, stem 
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cell transplantations have shown some therapeutic efficacy in preclinical models of AD by 
modulating complex biological systems via multiple mechanisms. Although the short-term 
benefits of stem cell transplantation appear promising and warrant further investigation, 
these studies have also shown that NSCs do not modify the underlying Aβ or tau pathology. 
[3,4]
 Moreover, given the widespread and progressive damage that is found in the brain of 
AD patients, it is highly unlikely that the mechanisms that are typically in place to guide the 
differentiation of NSCs to new neurons for neuronal cell replacement remains intact. [124] 
Hence, therapeutic strategies that utilize combinatorial approaches aimed at not only 
improving synaptic connectivity and neuronal function but also diminishing Aβ and tau 
accumulation as well as potentially guiding stem cell differentiation in vivo would have 
immense benefit.
For this purpose, Blurton-Jones et al. recently hypothesized that NSCs could provide an 
effective means with which to deliver disease-modifying therapeutic proteins owing to the 
fact that NSCs can migrate to diseased areas found in the AD brain. [125] In particular, 
murine NSCs were transfected with a plasmid vector encoding the Aβ-degrading enzyme, 
neprilysin (sNEP), using an AMAXA nucleofector. It was found that engineering the NSCs 
(sNEP-NSCs) with sNEP did not negatively affect their multipotency or differentiation 
capability. More importantly, these sNEP-NSCs were found to significantly reduce Aβ levels 
both in vitro and in vivo. Specifically, in the in vivo studies, these sNEP-NSCs, were 
transplanted (100 000 cells per animal) into the subiculum or hippocampus of AD transgenic 
mice (9-month or 18-month-old 3xTg-AD mice) as both of these regions have previously 
been shown to develop robust Aβ plaque pathology, exhibit significant synaptic 
degeneration, and are critical for learning and memory. One or three months following 
transplantation of the engineered NSCs, animals were sacrificed and their brains were 
examined. The sNEP-NSCs were found to engraft well and migrate into the surrounding 
brain tissue. Importantly, Aβ levels were assessed and significant reductions in plaque 
density in areas adjacent to the sNEC-NSC grafts were observed. While NFT levels were 
unchanged, sNEC-NSC grafts did result in a 31.8% increase in synaptic density when 
compared to the transplantation of control NSCs. Finally these findings were confirmed in a 
second AD model (Thy1-APP mice) further demonstrating the potential therapeutic benefits 
of engineered stem cells for AD treatment.
In support of the NEP engineered stem cell approach, Lebson and colleagues transfected 
CD11b+ monocytes with NEP and infused them biweekly into AD transgenic mice. [126] 
These engineered monocytes were able to migrate into the brain, resulting in a decrease in 
the rate of Aβ deposition. However, the use of monocytes as a cell source has disadvantages 
when compared to stem cells, as monocytes have limited half-lives (1–3 days) and thereby 
require repeated injections. Though, one advantage of these repeated injections is the fact 
that it can protect against potential adverse events that are typically associated with the 
transplantation of engineered stem cells such as teratoma formation or random insertion of 
the engineered gene into the host genome. Repeated injections can also prevent potential 
adverse events that could be associated with prolonged therapeutic gene expression.
Lastly, in 2005, Tuszynski et al. conducted a phase 1 clinical trial on the suitability of nerve 
growth factor (NGF) gene therapy for the treatment of AD. [127] In their study, basal 
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forebrain grafts of engineered fibroblasts that produce nerve growth factor (NGF), which 
counteracts cholinergic neuronal death, via modified Molony leukemia virus vectors, were 
injected into eight patients with mild AD. After a mean follow-up of 22 months in six 
subjects, no long-term adverse effects were observed. Importantly, serial PET scans showed 
significant increases in cortical 18-flurodeoxyglucose (Figure 3 ). Moreover, one subject 
demonstrated robust growth responses to NGF. These findings suggest improvement and a 
possible reversal of clinical outcome demonstrating the great potential of engineered cells 
for the treatment of AD. Although fibroblasts were engineered in this study, it is easy to 
imagine engineering stem cells for the same purpose, which would likely enhance the 
therapeutic effects seen, as the stem cells can specifically migrate to diseased areas in AD 
patients. In addition, besides using NSCs, other cell types may be useful for the delivery of 
NEP or NGF to the AD brain. For example, iPSC-derived NSCs can be used for 
personalized cell therapies against AD. Similarly, MSCs represent a readily available stem 
cell source that has seen utility in other diseases of the brain.
Overall, while this field is still in the nascent stages of development, owing to the promise 
that stem cell transplantations have already shown for the treatment of AD via the 
improvement of synaptic connectivity and neuronal function, the addition of engineered 
stem cells that secrete factors that can reduce Aβ and tau accumulations and/or guide stem 
cell differentiation in vivo would have immense therapeutic benefits.
3.1.3. Parkinson’s Disease—Parkinson’s disease (PD) is a progressive 
neurodegenerative disorder that affects dopaminergic motor neurons of the ventral midbrain 
and their terminal projections thereby resulting in movement-related symptoms (e.g., 
shaking, rigidity, difficulty walking, and gait) and in later stages, thinking and behavioral 
problems (e.g., dementia and depression). [128] Strategies that focus on dopamine 
replacement have proven effective at remediating some motor symptoms during the course 
of PD. However, they ultimately fail to deliver long-term disease modification. Moreover, 
they lose effectiveness due to the emergence of additional side effects. [129] As such, several 
strategies have been investigated as alternatives for the treatment of PD, including direct cell 
replacement and gene transfer through viral vectors. For instance, the transplantation of 
human fetal ventral mesencephalic tissues, which secrete dopamine, into the striatum of 
Parkinson’s patients has shown promise. However, fetal tissue transplantation is problematic 
due to the logistics involved in acquiring large volumes of this tissue as well as the ethical 
questions associated with such treatments. [130] As an alternative, transplantation of stem 
cells that are differentiated along a dopaminergic lineage could offer a promising route of 
therapy with the hypothesis that these cells could act as a substitute for pharmacotherapy to 
directly provide long-term dopamine secretion. [131] Besides differentiation, other 
investigations involving gene therapy for PD have primarily focused on: 1) the restoration of 
dopamine synthesis and 2) neuroprotection and restoration of the surviving host 
dopaminergic circuitry through the introduction of trophic factors. [132]
While the majority of studies have focused on utilizing these strategies separately, recent 
efforts have increasingly focused on engineering stem cells to combine the benefits of stem 
cell and gene therapy for the treatment of PD. For instance, a number of studies have already 
investigated the engineering of various cell types (e.g., fibroblasts [133] and endogenous 
Yin et al. Page 19
Adv Healthc Mater. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
striatal cells [134]) with tyrosine hydroxylase (TH), the rate-limiting enzyme in 
catecholamine biosynthesis that converts tyrosine into L-DOPA. However, engineering these 
cell types to produce TH only resulted in a partial restoration of the behavior and 
biochemical deficiencies in PD animal models.
To address this, Kim and co-workers engineered NSCs to produce a combination of L-
DOPA, TH, and GTP cyclohydrolase I (GTPCH1), which is a key enzyme in the synthesis of 
tetrahy-drobiopaterin, [135] a cofactor that supports TH activity. [136] In particular, human 
NSCs were transduced with retroviral vectors encoding TH and GTPCH1. Following 
transduction, the amount of L-DOPA produced by these engineered NSCs was significantly 
higher than unengineered NSCs or NSCs that were only transduced with the TH gene. 
HPLC results indicated that L-DOPA production in engineered NSCs (750 ng/10 6 cells/day) 
was 800 to 2000- fold greater than unengineered controls (0.35 ng/10 6 cells/day) or TH-
transduced NSC lines (0.92 ng/10 6 cells/day). To test the ability of the engineered NSCs to 
produce functional improvements, they were transplanted in the striata of hemiparkinsonian 
rats. It was observed that the engineered NSCs survived well in the adult host brain after 
transplantation without any signs of rejection. More importantly, while some of the grafted 
cells did migrate away from the injection site into the surrounding host tissue, they 
maintained high levels of TH expression up to 4 weeks after transplantation. As a result, 
functional improvements were seen suggesting that engineered NSCs expressing both TH 
and GTPCH1 could have great potential for the treatment of PD.
Lastly, Tan et al. recently demonstrated that engineering NSCs with both Nurr1 and Brn4 
could dramatically increase the differentiation and maturity of TH-expressing dopaminergic 
neurons. [137,138] In particular, Nurr1 is a member of the steroid/thyroid hormone orphan 
nuclear receptor family and is one of the most important factors that are expressed in 
dopaminergic neurons. [139] On the other hand, Brn4 is a member of the POU-homeodomain 
family of transcription factors and plays an important role in regulating neuron migration 
and differentiation. [140] As such, Tan and colleagues hypothesized that the combination of 
Brn4 and Nurr1 could synergistically induce NSCs to differentiate into mature and 
functional dopaminergic neurons more effectively than either factor alone. Following the co-
delivery of plasmids encoding Nurr1 and Brn4 via electroporation, as expected, engineered 
NSCs were found to exhibit high levels of Nurr1 and Brn4. More importantly, these cells 
efficiently differentiated into TH-expressing dopaminergic neurons and there were 
significantly more DAT positive cells when compared to controls, suggesting that the co-
expression of Nurr1 and Brn4 resulted in more mature neurons. Finally, to validate this 
strategy in vivo, the authors investigated the effect of transplanted engineered NSCs in a rat 
PD model. It was observed that the overexpression of Nurr1 alone was able to promote NSC 
differentiation into dopaminergic neurons in vivo and increased the level of DA in the 
striatum (Figure 4A), resulting in behavioral improvement of PD rats. More importantly, the 
co-expression of both Nurr1 and Brn4 in NSCs significantly increased the maturity and 
viability of these dopaminergic neurons compared to all other conditions (Figure 4B).
3.1.4. Stroke—Currently, the only therapies that are available for stroke are intervention to 
prevent inappropriate coagulation, surgical procedures to repair vascular abnormalities, and 
thrombolytic therapy with nothing directed at the restoration of function following stroke. 
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As such, recent efforts have focused on the use of stem cell-based therapies to replace lost 
neurons and promote the survival and differentiation of both surviving and transplanted 
cells. [141] For instance, BM-derived MSCs have been shown to differentiate into neuronal 
cells, cross the blood-brain barrier (BBB), migrate to areas of damage, and secrete growth 
factors and cytokines. [142] Moreover, transplantation following stroke has resulted in 
observable improvements in functional recovery. [143] However, to further improve the 
efficacy of stem cell therapies for stroke, thereby enhancing their clinical potential, recent 
efforts have focused on engineering stem cells with neuroprotective factors as well as factors 
that promote neurite outgrowth.
To this end, Zhao et al. engineered BM stromal cells with hepatocyte growth factor (HGF) 
via a multimutated herpes simplex virus type-1 (HSV-1) vector (MSC-HGF). [144] In 
particular, HGF has numerous functions including anti-apoptosis, angiogenesis, 
motogenesis, morphogenesis, tissue regeneration, and the enhancement of neurite 
outgrowth. Moreover, it can inhibit BBB destruction and provide neuroprotection following 
brain ischemia. In the present study, Zhao and co-workers found that the HSV-1 vector was 
able to transfer the HGF gene to the MSC population with high efficiency in vitro and, more 
importantly, the engineered MSCs functioned in vivo resulting in the expression and 
maintenance of high levels of the HGF. To evaluate the therapeutic efficacy of this 
engineered stem cell therapy, the authors treated brain ischemia in the superacute and acute 
therapeutic phases using a rat transient middle cerebral artery occlusion model. [145] The 
engineered stem cell therapy showed significant improvements in terms of the reversal of 
neurological deficits when compared to the MSC transplantation alone (Figure 5). In 
addition, after transplantation in the superacute therapeutic phases, Zhao and colleagues 
detected abundant levels of HGF protein in the ischemic brain of the MSC-HGF treated 
group, which was maintained for at least 2 weeks. Finally, the percentage of apoptosis-
positive cells in the ischemic boundary zone was significantly decreased following treatment 
with MSC-HGF when compared to MSCs alone and other control conditions.
Similarly, Lee and co-workers sought to provide neuroprotection by engineering human 
NSCs with Akt1 via a retroviral vector. [146] Akt was chosen because it is a serine/threonine 
kinase that plays a critical role in the modulation of cell proliferation, growth, and survival 
by participating in the PI3K/Akt signaling pathway. [147] Moreover, previous studies have 
demonstrated that Akt can promote cell survival during free radical exposure or hypoxia in 
hippocampal neurons. [148] As such, Lee et al. hypothesized that engineering NSCs with Akt 
could mediate survival and improve functional recovery following stroke. In particular, 
previous work has demonstrated that human NSCs can ameliorate neurological deficits in 
animal models of various diseases including PD [136] and stroke following their 
transplantation into the brain or spinal cord. [136,149] However, the survival rate of grafted 
NSCs in ischemia and ICH rats is very low (less than 50% of grafted NSCs survived in a 
mouse model of stroke 2-weeks post transplantation and 30% after 8-weeks) and, as such, is 
a grave concern that needs to be addressed in order to facilitate translation of NSC 
transplantation to the clinic. [150] Addressing this issue, NSCs expressing Akt1 were found 
to be highly resistant to H2O2-induced cytotoxicity in vitro. Following transplantation in the 
brain of a mouse model of stroke, engineered NSCs induced behavioral improvement and 
significantly increased cell survival (50–100% increase) at 2 and 8 weeks post- 
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transplantation as compared to parental NSCs. Brain transplantation of NSCs overexpressing 
Akt1 in a mouse model of stroke provided functional recovery as demonstrated by the 
rotarod and neurology scores 8 weeks post-transplantation. Furthermore, it was determined 
that the Akt1 engineered NSCs enhanced survival as well as differentiation of the grafted 
NSCs into astrocytes and neurons owing to factors in the local microenvironment. 
Collectively, these results suggest that the Akt1 engineered NSCs could be of great value for 
the cellular therapy of stroke by enhancing survival of grafted NSCs.
Finally, following a slightly different strategy, Onda and colleagues demonstrated that 
engineering MSCs with angiopoi-etin-1 (Ang-1) could enhance functional recovery 
following cerebral ischemia by improving angiogenesis near the border of the ischemic 
lesions. [151] In particular, Ang-1 was used for this purpose as it is involved in the 
maturation, stabilization, remodeling of vessels, [152] and has specifically been shown to 
promote angiogenesis in the brain. [153] Furthermore, Ang-1 protects peripheral vasculature 
from leakage, [154] which may account for its anti-edematic effects if introduced following 
cerebral ischemia. As such, while the transplantation of unadulterated MSCs has been shown 
to ameliorate functional deficits via both neuroprotection and angiogenesis, Onda and 
coworkers hypothesized that there could be significant room to improve MSC 
transplantation strategies by engineering MSCs with Ang-1. Towards this objective, 
adenovirus-mediated gene transduction was performed to engineer MSCs with Ang-1. [143] 
Using a rat middle cerebral artery occlusion (MCAO) model of stroke, the authors 
demonstrated that intravenous infusion of either MSCs or Ang-MSCs 6 h after stroke 
induction resulted in a reduction in infarction volume, initiation of angiogenesis, and 
behavioral improvements. When comparing Ang-MSCs to MSCs, the authors reported a 
modest but observable improvement in Ang-MSC treated animals compared to unengineered 
MSC treated animals. While a significant enhancement was not seen, this suggests that 
MSCs alone, or with the proper genetic modification to enhance angiogenesis may provide 
additional functional benefits for the treatment of ischemia after stroke.
3.2. Engineering Stem Cells for Musculoskeletal Regeneration
As with other applications in regenerative medicine, stem cell-based therapies have shown 
great promise for the treatment of numerous musculoskeletal diseases and injuries. In 
particular, MSCs, ESCs, and iPSCs have all been shown to have the ability to produce 
tissues from various lineages that are critical for musculoskeletal regeneration, and allow for 
the derivation of tissues that are comprised of multiple cell types. Currently, most strategies 
for stem cell-based musculoskeletal regeneration have focused on direct injection of stem 
cells and, more recently, transplantation in combination with biomaterial scaffolds and 
bioreactors, which can provide an environment that better supports tissue formation. 
However, there is still significant room to improve stem cell-based therapies for 
musculoskeletal regeneration by more precisely guiding their behavior in vivo. This can be 
accomplished by engineering stem cells to express factors that specifically guide 
differentiation towards bone or cartilage lineages. As such, in this section we will highlight 
the progress that has been made in utilizing engineered stem cells for bone and cartilage 
regeneration.
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3.2.1. Bone Regeneration—The primary function of bones is to provide shape, 
mechanical support, and protection for the body while facilitating movement. [155] On the 
other hand, bones also play an equally important role in mineral homeostasis and participate 
in the regulation of energy metabolism. [156] Typically, bones are supplied by blood and 
constantly undergo remodeling, allowing them to adapt to mechanical stress, maintain bone 
health, and repair small injuries. In particular, osteoclasts are the specialized bone cells that 
are responsible for the resorption of bone tissue while osteoblasts are the cells responsible 
for bone formation. However, clinical situations can arise where injuries, congenital 
malformations, or diseases cause large bone defects that cannot be repaired by natural 
mechanisms. Currently, autologous grafts, which contain the essential components necessary 
for bone regeneration (e.g., osteogenic cells, osteoinductive growth factors, and bone-
supporting matrix), are the gold standard of treatment. However, they are not available in 
every clinical situation and autologous grafts can result in morbidity at the donor site as well 
as difficulties in preparing anatomically shaped grafts from the harvested bone. As such, 
there is a critical need for techniques that allow for specifically controlled bone regeneration.
To address these issues, a variety of engineering approaches have been investigated. 
Currently, the development of scaffolds is leading this area of research; wherein scaffolds 
using various materials, structures (e.g., pore size, roughness), cell attachment sites, and 
biomechanical properties have been studied extensively for musculoskeletal regeneration 
and have been reviewed elsewhere. [157] However, choosing which cell type with which to 
seed these scaffolds and achieving precise control over the differentiation of these cells are 
equally important issues that must be taken into consideration. In particular, stem cells, 
especially BM-derived MSCs, have been the most studied cells for this purpose. [158] As 
mentioned previously, MSCs have the ability to differentiate into bone, cartilage, adipose, 
muscle, tendon, ligament, and marrow stroma. BM transplantations are already used 
clinically in combination with osteoconductive materials to augment bone healing. [159] 
Moreover, MSCs have been shown to induce rapid bone regeneration and fracture repair in 
vivo in several models of bone loss including long bones, the calvaria, and the spine. Owing 
to the great promise that MSC transplantations, either with or without scaffold, hold for bone 
repair, one avenue of particular interest has focused on engineered MSCs as well as other 
cell sources to provide additional, more precise, control over their differentiation to 
osteoblasts and osteoclasts.
One commonly used strategy to engineer stem cells for bone regeneration has focused on 
genetically modifying stem cells with members from the bone morphogenetic protein (BMP) 
family of genes. [160] BMPs are a prime candidate as they have been found to play an 
important role during skeletal patterning and bone formation and are the most potent 
osteoinductive agents available today. For instance, recombinant BMP-2 has been approved 
by the FDA for the treatment of acute open tibial shaft fractures and for inducing lumbar 
spine fusion in patients with degenerative disk disease. [161] Following this strategy, 
Steinhardt and co-workers engineered maxillofacial BM-derived MSCs to overexpress 
MBP-2 via an adenoviral vector. [162] These engineered MSCs expressed high levels of 
BMP-2 protein resulting in differentiation towards an osteogenic lineage in vitro as well as 
significant bone formation in an ectopic site in vivo. In addition, implantation of the 
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engineered MSCs into a mandibular defect led to regeneration of tissue at the site of the 
defect, which was confirmed via microcomputed tomography analysis. In particular, in vivo 
osteogenic differentiation as well as bone tissue regeneration was confirmed.
Further advancing BMP-based bone regeneration strategies, Virk et al. developed a “same 
day” methodology wherein patient-derived MSCs were engineered to overexpress BMP-2 
via a lentiviral vector (Figure 6).[163] The typical viral procedure used to engineer stem cells 
consists of a two-step process, wherein stem cells are first harvested, expanded ex vivo, and 
followed by infection with the BMP-2 (or other gene) viral vector. This requires time and 
special culture facilities before they can be transplanted for bone regeneration or for other 
applications. To circumvent this step, Virk and colleages sought to determine whether MSCs 
could be harvested, tranduced with a lentiviral vector-expressing BMP-2, and then 
transplanted in the same sitting. To accomplish this, buffy coat cells were harvested from the 
rat BM, transduced with the lentiviral vector for 1 hour, and then implanted into a rat 
femoral defect (Figure 6A–E). It was found that there was no significant difference (p = 
0.22) when comparing the healing rates of femoral defects that were treated with the “same 
day” strategy versus the traditional two-step lentiviral approach (Figure 6F,G). However, 
importantly, the “same day” strategy was found to induce earlier bone healing and higher 
bone volume (as analyzed via micro-computed tomography). As such, the “same day” 
strategy represents a significant advancement for the field of stem cell engineering as it 
offers a solution to the limitations that are typically associated with the culture expansion 
process that is required for the traditional ex vivo approach and can be applied to other 
engineered stem cell applications.
More recently, non-viral strategies to engineer stem cells for bone regeneration have been 
the primary focus of investigation. To this end, Sheyn et al. engineered adult porcine 
adipose-derived stem cells to transiently overexpress BMP-6 via nucleofection of a BMP-6-
encoding plasmid vector. [164] To test their engineered stem cells, bone void defects were 
created in the coccygeal vertebrate of nude rats and the engineered MSCs, which were 
suspended in a fibrin gel, were injected into the void. Beginning two weeks after treatment, 
it was found that considerable repair of the defect was observed in rats transplanted with the 
engineered MSCs. In addition, treatment with engineered stem cells induced bone formation 
at a rate that was twice as fast as the fibrin gel control group resulting in 2-fold higher bone 
volume when assayed at the end point. Finally, after twelve weeks, treatment with 
engineered MSCs resulted in complete regrowth of the void. Specifically, the engineered 
MSC condition reached a bone volume similar to that found in the native vertebrate and 
immunostaining indicated that the engineered MSCs contributed to the observed new bone 
formation.
To further enhance in vivo ectopic bone formation, Hosseinkhani and co-workers 
investigated combining engineered MSCS, which transiently express BMP-2 via a plasmid 
vector, with a three-dimensional (3D) cell scaffold as well as a bioreactor perfusion system 
thereby combining numerous beneficial factors to enhance bone formation. Specifically, the 
scaffold was composed of a collagen sponge reinforced with poly(glycolic acid) (PGA) 
fibers, which were impregnated with a cationized gelatin-DNA complex (via the 
introduction of spermine). [165] When cultured in vitro, it was found that BMP-2 expression 
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was significantly enhanced in the perfusion culture condition versus static culture. Moreover, 
in vivo, following subcutaneous implantation into the back of rats, homogenous bone 
formation was observed throughout the scaffolds (from all conditions), with the extent of 
bone formation being highest in the engineered stem cell condition in combination with 
scaffold support and perfusion culturing. Finally, the level of alkaline phosphatase activity 
and osteocalcin content at the implanted site were significant higher in the combined 
engineered stem cell condition compared to the other controls. This demonstrates that 
engineering stem cells can act synergistically and be combined with traditional scaffold 
strategies to enhance bone formation.
Lastly, as bone formation typically involves multiple factors that not only include a 3D 
microenvironment (e.g., scaffold) to support bone growth, as well as bone-specific gene 
expression (e.g., BMP family), Huang et al. developed a PLGA scaffold that could be loaded 
with both osteogenic and angiogenic factors. [166] PLGA was chosen, as it is a widely used 
biomedical polymer that has been safely used as a biodegradable suture and implant for 
several decades. [167] In particular, loading of BMP-4 plasmid vector was achieved by 
precomplexing with PEI, followed by lyophilization. Freeze-dried PEI DNA condensates 
and a mixture of alginate and VEGF were then combined with PLGA to fabricate the 
scaffold, which was accomplished via a high pressure gas foaming process. [168] In 
particular, alginate was used because previous studies have shown that this mixture can 
attenuate release of VEGF from PLGA scaffolds. [169] It was found that any combination of 
the factors displayed increased bone formation when compared to the individual factors 
alone. Moreover, combining these factors led to the greatest quantity and quality of new 
bone tissue, suggesting that the use of a scaffold combined with angiogenic and osteogenic 
factors could act synergistically to regenerate bone tissue. The authors hypothesized that this 
could be caused by increased survival of transplanted cells owing to VEGF-mediated 
angiogenesis along with the direct osteogenic action of BMP-4 on this cell population.
3.2.2. Cartilage Regeneration—Defects in articular cartilage tend to heal poorly and 
progress to catastrophic degenerative arthritis. Typically, articular cartilage is a thin 
viscoelastic layer that is less than 3 mm thick, which covers the articulating surface of the 
bone in a joint thereby permitting smooth motion with minimal friction. At a fundamental 
level, cartilage is composed of a unique ECM that consists of a complex combination of 
specifically arranged collagen II fibrils. In addition, these fibrils have large water-retaining 
molecules known as aggrecan as well as its associated linked protein molecules bonded to it. 
This unique ECM is produced and maintained by a limited number of chondrocytes and 
gives articular cartilage its ability to withstand the repetitive compressive loading in daily 
activities without undergoing premature repair. [170] This entire structure is avascular, 
aneural, and alymphatic and as such, cell infiltration and repair after injury is unlikely to 
occur. [171] Current surgical intervention include the transplantation of autologous 
chondrocytes that have been expanded in vitro, which is known as autologous chondrocyte 
implantation (ACI). [172] Unfortunately, ACI is associated with several problems such as 
donor site morbidity, loss of chondrocyte phenotype upon ex vivo expansion and inferior 
fibrocartilage formation at the defect site. [173] Other clinical procedures are also available, 
including arthroscopic lavage and debridement, microfracture techniques, and osteochondral 
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transplantation. [174] While there have been some promising results, most cartilage repair 
techniques lead to fibrocartilage formation and cartilage degeneration after a temporary 
relief of symptoms. As such, the most effective procedure utilizes surgical replacement with 
an autograft. However, there is a shortage of articular cartilage that can be donated for 
autografting.
Stem cells represent a promising cell source for cartilage repair and can be derived from two 
major sources: MSCs and ESCs. [175] For example, BM-derived MSCs are currently 
undergoing clinical trials for several orthopedic applications including articular cartilage 
repair. [176] However, there are still some limitations to directly transplanting stem cells for 
this purpose including the need for a scaffold as well as specifically guiding stem cell 
differentiation to cartilage. As such, there is significant room to improve stem cell-mediated 
cartilage repair.
3.2.2.1. Sox Family: The majority of strategies have focused on engineered MSCs with the 
SOX family of genes. The SOX family encodes transcription factors including SOX5, 
SOX6, and SOX9, which have all been shown to be the master regulators of chondrogenic 
differentiation. [177] In particular, SOX9 is expressed in all chondroprogenitors and 
chondrocytes, ensures cell survival in precartilaginous condensations, and is required to 
activate cartilage genes such as Col2a1, Agc1. [178] Similarly, SOX5 and SOX6 are 
expressed in prechondrocytes and has been shown to enhance chondrogenic specific gene 
transcription cooperatively with SOX9. [179] As such, this SOX trio, with a minimum of 
SOX9, is required and sufficient to mediate chondrogenesis via activation of cartilage-
specific target enhancers such as aggrecan and Collagen-2. With this in mind, Park et al. 
demonstrated a non-viral method to engineer MSCs with a combination of the SOX trio to 
guide chondrogenesis. [180] Specifically, they utilized PEI-modified PLGA nanoparticles to 
complex with and deliver plasmids encoding SOX5, SOX6, and SOX9 (size distribution of 
60 ± 11, 72 ± 8, and 92 ± 11 nm for the PLGA, PEI-modified PLGA, and PEI-modified 
PLGA/gene complexes, respectively). All three genes were efficiently delivered with a 
transfection efficiency of 22.21% for MSCs resulting in the synthesis of chondrocyte-related 
proteins well after three weeks in vitro. Moreover, engineered cells showed a high amount of 
staining for proteoglycans and polysaccharides, which further demonstrate their successful 
chondrogenic differentiation.
Similarly, Im and co-workers also engineered MSCs with the SOX trio using a PLGA-based 
non-viral method. [181] In this case, the plasmid (encoding the SOX trio) was complexed 
with a PEI-PEG polymer and then incorporated into a PLGA scaffold, [182] which allowed 
for slow release of the plasmid to MSCs seeded in the scaffold. The pDNA was released 
over 30 days and the MSCs were successfully transfected as demonstrated by a 50-fold 
increase in gene expression of SOX5, SOX6, and SOX9. An immunofluorescence study also 
demonstrated the uptake of pDNA into the MSCs and translation into protein up to 21 days 
after transfection. More importantly, the usefulness of their system was corroborated by in 
vivo implantation of the MSC/SOX trio pDNA-incorporated PLGA scaffolds into 
osteochondral defects created in rabbits. Increased expression of chondrogenic markers and 
a smooth articular surface with restoration of hyaline cartilage was observed in the 
engineered stem cells (MSC/pDNA-incorporated PLGA scaffolds) when compared to the 
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PLGA scaffold alone, wherein the defect area was depressed and filled with fibrous tissue, 
and MSC/PLGA scaffold without plasmid, wherein regeneration was observed but the 
quality of repair was poorer with an irregular surface and incomplete reconstitution of 
subchondral bone (Figure 7). Similar to what was discussed in bone regeneration, these 
findings demonstrated the potential effectiveness of combining engineered stem cells 
(expressing SOX trio) with scaffold-based strategies for in vitro and in vivo cartilage tissue 
engineering.
3.2.2.2. Transforming Growth Factor Family: An alternative approach for cartilage 
regeneration has been the genetic modification of stem cells with members of the 
transforming growth factor (TGF) family. In particular, previous studies have demonstrated 
that the addition of TGF-β1 to MSCs can induce chondrogenesis. [183] As such, Pagnotto et 
al. investigated the ability of adeno-associated virus (AAV) to effectively transduce MSCs 
with TGF-β1 to induce chondrogenesis in vitro and in vivo. [184] To this end, adult MSCs 
were transduced with AAV-GFP (control) or AAV-TGF-β1 and studied in pellet cultures. For 
in vivo studies, AAV–GFP and AAV–TGF-β1-transduced MSCs were implanted into 
osteochondral defects of athymic rats. Following implantation, GFP was detected using 
fluorescent microscopy. GFP transgene expression was observed in 100% of the GFP 
implanted defects after 2 weeks, 67% after 8 weeks, and 17% after 12 weeks of 
implantation. More importantly, cartilage repair was assessed using gross and histological 
analysis at 4, 8 and 12 weeks. Improved cartilage repair was observed in osteochondral 
defects implanted with AAV–TGF-β1-transduced MSCs at 12 weeks (p = 0.0047). These 
results demonstrate that AAV, which has been proposed to be safer than other viral methods, 
is a suitable vector for gene delivery to improve the cartilage repair potential of MSCs.
Similarly, it has been shown that TGF-β3 can effectively induce chondrogenesis of MSCs, 
whereas other potential transgenes (e.g., BMP-7, SOX9) were less effective. [185] In this 
case, Brunger and colleagues developed a bioactive scaffold that could guide stem cell 
differentiation and, together with stem cells, act as a suitable replacement of musculoskeletal 
tissues with mechanical properties that mimic those of native tissues. [185] In particular, the 
motivation behind this study was to develop a scaffold that was not only able to mediate 
differentiation but also to guide the formation of ECM that has the biomechanical 
composition and mechanical features that mimic native tissue properties. Towards this 
objective, lentiviral vectors immobilized with PLL, which has previously been shown to 
facilitate efficient transduction of cells, [186] was used to functionalize poly(e-caprolactone) 
(PCL), one of the most commonly used polymers for tissue engineering scaffold 
applications. [187] The authors first demonstrated that PCL could immobilize the lentivirus to 
PLL films and facilitate MSC transduction (93% transfection efficiency of EGFP vs fewer 
than 1% in the absence of PCL). They then demonstrated that scaffold mediated gene 
delivery of TGF-β3, using a 3D woven PCL scaffold, induced robust cartilaginous ECM 
formation (Figure 8A,B). Specifically, it was found that this method resulted in the 
production of 17 ng/mL of TGF-β3 as well as high levels of sulfated glycosaminoglycan 
(sGAG) and collagen production (Figure 8C,D). Importantly, chondrogenesis induced by 
scaffold-mediated gene delivery was as effective as traditional differentiation protocols 
involving medium supplementation with TGF-β3, as assessed by gene expression (e.g., α1 
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chains of collagen type 1, 2, and 10 as well as aggrecan), and biochemical (e.g., total 
collagen and sGAG content), and biomechanical analyses.
3.2.2.3. Non-Viral Methods: Lastly, while the majority of approaches used to engineer stem 
cells for chondrogenesis have focused on viral delivery methods, Jeon et al., recently 
reported the development of nanoparticles for the co-delivery of Cbfa-1 siRNA and SOX9 
protein to specifically guide chondrogenesis while inhibiting osteogenesis (Figure 9).[188] As 
mentioned previously, SOX9 is an essential chondrogenic differentiation-related protein, 
which triggers the expression of aggrecan and collagen type 2. [189] However, simply adding 
SOX9 protein to the culture medium is not a viable strategy due to rapid degradation. On the 
other hand, Cbfa-1 is an osteogenesis-related transcription factor that typically inhibits the 
chondrogenesis of MSCs. As such, to enhance chondrogenesis, it would be beneficial to 
silence Cbfa-1 while activating SOX9. [190] To this end, the authors fabricated PLGA 
nanoparticles loaded with SOX9 protein and coated with Cbfa-1 siRNA (Figure 9A). 
Specifically, the PLGA nanoparticles were fabricated by solvent evaporation and water-in-
oil-in-water emulsion, resulting in 53 nm nanoparticles. To deliver siRNA, the PLGA 
nanoparticles were coated with PEI, which allowed for complexing with siRNA, resulting in 
68 nm and 138 nm diameter particles, respectively with a final zeta potential of +26.3 mV. 
Further characterization included evaluation of the release of SOX9 protein from the PLGA 
nanoparticles as well as confirmation of the ability of cells to uptake/internalize the 
nanoparticle complexes. Importantly, upon internalization of the PLGA nanoparticles coated 
with Cbfa-1 siRNA and loaded with SOX9 protein into MSCs, the level of Cbfa-1 protein 
was reduced whereas the level of SOX9 protein was increased.
Finally, to test the ability of these nanoparticles to induce differentiation of MSCs, both in 
vitro and in vivo studies were conducted and markers typically expressed in mature 
chondrocytes were examined (e.g., SOX9, aggrecan, COMP, and COL II). In vitro, three 
weeks after the initiation of differentiation via the delivery of nanoparticles, it was observed 
that the mature markers were highly expressed at the mRNA and protein levels in engineered 
MSCs compared to unengineered controls. By contrast, these cells did not express 
osteogenesis related markers (Cbfa-1 and COL1). In vivo, MSCs were injected into nude 
mice following internalization of PLGA NPs coated with Cbfa-1-targeting siRNA and 
loaded with SOX9 protein. When the injection site was excised, markers of chondrogenesis 
were found to be highly expressed at the mRNA and protein levels, corroborating the in vitro 
results. Moreover, the level of GAG was much higher in engineered MSCs then in control 
MSCs. Lastly, ECM production, as assessed by Alcian blue, Safranin-O, and Masson’s 
Trichrome staining, was evident in the excised samples.
3.3. Engineering Stem Cells for Cardiac Repair
Although substantial progress has been made in treating various heart conditions, the 
worldwide burden of heart failure is enormous and is expected to continue growing 
throughout this century as the aging population increases in size. [191] Specifically, heart 
disease is the leading cause of death in the United States, where it accounts for nearly 40% 
of all deaths, which is more than all cancers-related deaths combined. [192] Similarly, 
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congenital heart defects occur in nearly 14 out of every 1000 newborn children and are the 
leading cause of death for children in their first years of life. [193]
Typically, the heart wall is composed of tightly packed myocytes and fibroblasts, with a 
dense supporting vasculature and collagen-based extracellular matrix (ECM). Owing to the 
high density and metabolic demand of these cells, the myocardium consumes a large amount 
of oxygen and is unable to tolerate hypoxia. [194] However, during myocardial infarction, a 
vigorous inflammatory response is elicited resulting in massive cell death. Over the weeks to 
months following infarction, fibroblasts and endothelial cells migrate to the site of infarction 
forming granulation tissue. This ultimately leads in the generation of a thick and stiff 
collagenous scar that reduces the contractile function of the heart thereby resulting in 
ventricle wall thinning and remodeling and ultimately causing heart failure. This is another 
clear situation where tissue engineering would be of great value, as it provides a method 
with which to reconstruct the heart following heart diseases or in patients with congenital 
heart defects. [192] However, similar to the issues presented previously with bone and 
cartilage regeneration, there is a need to determine which cell types to deliver and to develop 
methods with which to specifically control the differentiation of these cells as well as to 
enhance survival of remaining cells.
To this end, cell transplantations and scaffold-based tissue engineering approaches have 
utilized various cell types including skeletal myoblasts, [195] cardiomyocytes,[196] smooth 
muscle cells, [197] BM cells, [198] and HSCs [199] as promising therapeutics for cardiac 
regeneration following heart disease. [200] In particular, studies have demonstrated that the 
transplantation of these cell types into the myocardium is not only safe, but contributed to 
angiogenesis and improvements in cardiac function. [201] Among the various cell types 
investigated, MSC are an especially attractive stem cell source for cardiac regeneration as 
they are multipotent and are capable of differentiating into cardiomyocytes under the 
appropriate conditions. [202] Moreover, they express genes that encode for anti-inflammatory 
factors, anti-apoptotic factors, angiogenic factors, [203] and matrix-mediating factors, which 
may further enhance therapeutic recovery. [204]
To enhance stem cell-based therapies for cardiac repair, the development of engineered stem 
cells has focused on two strategies: 1) enhancing angiogenesis and the survival of remaining 
cardiomyocytes and 2) guiding stem cell differentiation specifically towards 
cardiomyocytes. In this section, we will discuss the progress that has been made with regard 
to both of these strategies. Moreover, we will introduce the use of optogenetics to 
specifically control cardiac tissue excitations and contraction and its potential in future 
engineered stem cell approaches for cardiac tissue regeneration.
3.3.1. Enhancing Angiogenesis and the Survival of Cardiomyocytes—Although 
stem cell transplantation for cardiac repair was initially aimed at inducing cardiac 
regeneration, our current understanding of the underlying therapeutic mechanisms suggests 
that stem cell therapy may limit maladaptive remodeling and improve heart function mainly 
through paracrine mechanisms. [205] As such, the majority of studies in this area have 
focused on demonstrating the use of stem cells to promote angiogenesis and promote heart 
function. For instance, MSC transplantation therapies can increase regional perfusion by: 1) 
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direct effects (e.g., vasculogenesis induced by implanted MSCs), and 2) paracrine effects 
(e.g., angiogenic factors or ateriogenic cytokines secreted by implanted MSCs). [206] To this 
end, Deuse et al. demonstrated the transplantation of mouse MSCs that were engineered to 
secrete either hepatocyte growth factor (HGF) or vascular endothelial growth factor (VEGF) 
via lentiviral vectors. [207] HGF and VEGF are cytokines that have previously been shown to 
exert strong proproliferatory and promigratory effects on MSCs thereby suggesting that a 
combination of engineered MSCs expressing these cytokines could prolong the survival of 
transplanted MSCs and subsequent regenerative effects. [208] To test these engineered stem 
cells, acute myocardial infarction was induced by coronary ligation. Deuse and colleagues 
determined that the transplantation of engineered MSCS, expressing either HGF or VEGF, 
resulted in greater improvement in postinfarction myocardial function than non-engineered 
MSCs. [207] In particular, it was reported that HGF- and VEGF-engineered MSCs were 
similarly potent in initiating angiogenesis, increasing the tolerance of cardiomyocytes to 
ischemia, reducing cardiomyocyte apoptosis, and resulting in a decrease in scar size and 
improved LV function in vivo. As such, engineered MSCs strongly upregulated cytokine 
production and augmented both autocrine and paracrine mechanisms involved in cell 
survival and myocardial recovery. Similarly, Guo et al. confirmed that engineering MSCs 
with HGF can significantly enhance angiogenesis via the expression of VCAM-1. [209] 
However, engineering MSCs with both HGF as well as granulocyte colony-stimulating 
factor (G-CSF), which regulates BM stem cell recruitment into the peripheral circulation and 
has been shown to enhance angiogenesis, [210] can further enhance angiogenesis and impart 
a synergistic effect thereby improving myocardial endothelial density, angiogenesis, 
geometric preservation, and heart function in an ischemic cardiomyopathy model.
Other factors that can improve transplanted cell survival and promote angiogenesis have also 
been investigated. For instance, Liu et al., engineered MSCs with angiogenin, which is a 
heparin-binding protein that interacts with endothelial cells to promote angiogenesis via the 
induction of a wide range of cellular responses including migration, [211] proliferation,[212] 
and tube formation. [213] While angiogenin activity is relatively low when compared to 
VEGF and fibroblast growth factor (FGF), it has a comparable angiogenic activity and 
reportedly decreases fibrosis thereby making it an ideal candidate for application to 
myocardial infarction. [214] With this in mind, Liu and co-workers engineered primary bone-
marrow derived MSCs to express angiogenin using adenoviral vectors. [215] It was observed 
that angiogenin modification of the MSCs greatly enhanced their survivability, allowing 
them to remain viable under low oxygen conditions (e.g., the number of engineered MSC 
deaths under hypoxic conditions was one-third that of non-engineered MSCs in vitro). In 
vivo, the engineered MSCs were transplanted into a myocardial infarction rat model, which 
was induced by ligating the left coronary artery. [216] After transplantation, they found that 
angiogenin modified MSCs survived over a long period of time and effectively expressed 
angiogenin protein for at least 6 weeks at the injected area. These results indicated that 
angiogenin may help the survival of transplanted MSCs, which also helps sustain the release 
of angiogenin. Moreover, the engineered MSCs enhanced myocardial vasculogenesis in the 
AMI rat model and demonstrated a significantly greater angiogenic and arteriogenic 
capacity than the group transplanted with untreated MSCs thereby inhibiting ventricular 
remodeling (Figure 10A,B). The border-zone wall was also found to be thicker and the 
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infarction area became smaller in engineered MSC group compared to non-engineered 
MSCs (Figure 10C–F). Finally and most importantly, the transplantation of engineering 
MSCs led to significant improvement in cardiac function (e.g., improved LV systolic and 
diastolic functions).
Similarly, several studies have reported that SDF-1α can promote the survival of 
cardiomyoctyes, MSCs, and other cell types via Akt activation. [217] As a result, Tang and 
colleagues hypothesized that MSCs engineered to secrete SDF-1α could greatly augment the 
survival of cardiomyoctyes and the transplanted MSCs. [218] It was found that SDF-1α 
engineered MSCs showed better survival ability when compared to non-engineered controls. 
They also demonstrated that the Ad-SDF-1-MSC transplantation enhanced VEGF 
expression in infarcted hearts in vivo. This suggests that the transplanted MSCs increased 
heart-tissue VEGF expression in the infarcted heart through paracrine mechanisms. 
Specifically, the authors proposed that the greater number of surviving MSCs could have 
produced more cytokines in the infarcted heart. [219] Overall, four weeks following 
transplantation, a reduced infarct size and fibrosis, greater vascular density, and thicker left 
ventricular wall were observed in the engineered MSC group compared to controls. 
Moreover, the measurement of haemodynamic parameters showed an improvement in the 
left ventricular performance in the Ad-SDF-MSC group as compared with other groups.
3.3.2. Controlling Stem Cell Differentiation to Myocardiocytes—As mentioned 
previously, the other strategy that is typically used to engineer stem cells for cardiac repair 
has focused on specifically guiding the differentiation of implanted stem cells to 
cardiomyocytes. To this end, Wang and co-workers investigated the ability of MSCs, which 
were engineered to secrete hypoxia-inducible factor 1α (HIF-1α), to differentiate toward 
cardiomyocytes. [220] Typically, HIF-1α regulates the transcription of genes that are 
involved in cell proliferation, survival, and differentiation. Owing to its central role in the 
oxygen-sensitive signaling pathway and previous findings that suggest a relationship 
between hypoxic microenvironments and the ability of MSCs to acquire a cardiomyocyte 
phenotype, [221] Wang et al. hypothesized that HIF-1α may play a key role in guiding this 
differentiation process. However, under normoxia, HIF-1α has a short half-life (≈5 min) and 
low transcriptional activity. As such, to prolong its half-life and further enhance its 
functionality, a HIF-1a mutant, wherein alanine (Ala) was substituted for proline (Pro) at 
position 564 and asparagine (Asp) at position 803, was produced to prevent HIF-1α 
hydroxylation resulting in a highly active form of HIF-1α. [222] Using this mutant HIF-1α, 
BM-derived rat MSCs were transfected via adenovirus. The authors found that when the 
engineered MSCs were co-cultured with cardiomyocytes, the engineered MSCs exhibited 
enhanced cardiac differentiation suggesting that the combination of co-culture with HIF-1α 
secretion was important in attaining efficient cardiac differentiation. Specifically, RT-PCR 
confirmed that HIF-1α activated TFG-β1 and SMAD, which are both upstream of the 
cardiac-specific transcription factors, NKx-2.5 and GATA-4. As a result of this high 
NKx-2.5 and GATA-4 expression, co-cultures with engineered MSCs exhibited 20% more 
differentiation than co-cultures with non-engineered MSCs.
In a subsequent study, Wang and co-workers determined that, in addition to guiding MSC 
differentiation towards cardiomyocytes, the use of HIF-1α could prevent apoptosis in 
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ischemic cardiomyocytes. [223] Specifically, previous studies have demonstrated that HIF-1α 
can decrease apoptosis of rat cardiomyocytes following simulated ischemia-reperfusion 
injury by inducing multiple protective genes. [224] In agreement with these results, Wang and 
colleagues determined that co-culturing cardiomyocytes with engineered MSCs (wherein 
cobalt chloride (CoCl2) was used to mimic hypoxic/ischemic conditions including 
generation of reactive oxygen species (ROS)) [225] increased expression of TGF-β1 and 
Bcl-2, concomitant with a reduction in the expression of caspase-3, LDH release, and 
TUNEL-positive cardiomyocytes when compared to non-engineered MSC-cardiomyocyte 
co-culture and cardiomyocytes alone. Overall, this suggests that HIF-1α can not only 
promote the differentiation of transplanted engineered MSCs towards cardiomyocytes but 
also limit the apoptosis of surviving ischemic cardiomyocytes.
3.3.3. Control Cardiac Tissue with Optogenetics—Finally, optogenetics has recently 
been applied to control the excitation and contraction of cardiac tissue. Electrical stimulation 
of heart muscle is typically achieved using an external electrical field that is applied locally 
to induce action potentials that are then propagated to electrically coupled neighboring cells. 
[226]
 However, this approach results in irreversible Faradaic reactions that produce toxic 
gases such as H2, O2, or Cl2 and alters the pH. [227] As a result, electrical stimulations can 
only be used for short depolarizations while long-lasting depolarizations are not feasible 
using this method. As such, at the end of 2010, Bruegmann et al. developed a method using 
channelrhodopsin-2 (ChR2), which is a light-sensitive trans-membrane protein that converts 
photons into transmembrane voltage through proton pumping, to stimulate heart muscle both 
in vitro and in vivo. [228] To accomplish this, they first generated a stable transgenic mouse 
embryonic stem cell line [229] expressing a mutant ChR2, ChR2(H134R), [230] where they 
demonstrated that inward currents could be induced by illumination with 475 nm light. Next, 
to obtain cardiomyocytes, embryoid bodies from the transgenic ESCs were generated and 
cardiomyocytes were identified by staining with muscle-specific protein α-actinin 
antibodies. At day 7 of differentiation, application of pulsed blue light reliably induced 
cellular contractions. Moreover, plating of ESC-derived cardiomyocytes on multielectrode 
arrays demonstrated that pulsed illuminations of one region could evoke electrical activity in 
this area with subsequent spreading to other regions. Finally, the authors demonstrated that 
ChR2 engineered cells could be used for the stimulation of the adult heart in vivo. In this 
case, transgenic mice were generated using the ChR-2 engineered ESCs. It was found that 
the ChR2 protein was located in the cell membrane of the ventricular cardiomyocytes 
(Figure 11A). Light application induced typical ChR2 currents in ventricular 
cardiomyocytes and more importantly, long-term depolarizations could be achieved, which 
resulted in a disturbance in the regular sinus rhythm with the generation of spontaneous 
ventricular extra-beats (Figure 11B–D). Overall, this method enabled precise localized 
stimulation and constant prolonged depolarization of cardiomyocytes and cardiac tissue 
resulting in alterations of pacemaking, Ca 2+ homeostasis, electrical coupling, and 
arrhythmogenic spontaneous extrabeats.
Building upon this work, Jia and colleagues developed the first nonviral strategy involving 
optogenetics that does not rely on embryogenesis in order to control the excitation and 
contraction of cardiac muscle. [231] Specifically, they took advantage of the heart’s high 
Yin et al. Page 32
Adv Healthc Mater. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
coupling aspect to develop a non-viral cell delivery system using a “tandem cell unit” (TCU) 
strategy, wherein a unit is composed of a host cardiomyocyte and a nonexcitable donor cell 
that carries exogenous ion channels (e.g., ChR2). To this end, they developed, characterized, 
and used a stable HEK cells expressing a variant of ChR2 as the donor cell delivery system. 
The TCU strategy was validated in vitro in cell pairs with adult canine myocytes and in 
cardiac syncytium with neonatal rat cardiomyocytes. Specifically, robust response was seen 
and similar conduction velocities and calcium transient morphologies were observed in 
localized electric and optical stimulation of cardiac syncytium. Overall, using the TCU 
strategy, light-triggered electric waves were found to be quantitatively indistinguishable 
from electrically triggered waves. Moreover, the viral-free method can allow for a safer 
alternative for in vivo applications such as light-driven cardiac pacemakers and muscle 
actuations. While the authors did not use stem cells in this case, one can imagine that this 
non-viral method can be equally applied to stem cells with the added benefits of specifically 
controlling differentiation or controlling the excitation and contraction of cardiac muscle 
using light.
4. Engineering Stem Cells for Cancer Therapy
Cancer is one of the leading causes of death worldwide and, in the United States alone, 
causes one in every four deaths. [232] Currently, surgical resection of the bulk tumor is the 
gold standard for treatment and is typically followed by a combination of chemotherapy and 
radiotherapy. However, despite this aggressive therapy, late stage cancers that have already 
metastasized are difficult to completely eradiate, thereby ultimately resulting in recurrence. 
This can be attributed to a number of reasons, including the significant heterogeneity that 
exists between patients and within each tumor, the lack of treatment selectivity thereby 
resulting in considerable loss of healthy tissue, and chemoresistance. [233] Of these issues, 
the lack of selectivity that is seen with conventional therapies is arguable the largest 
drawback towards the effective treatment of cancer. Recent therapies are being developed 
with increased targeting in mind. For instance, hormone therapies have been developed for 
cancers of the sexual organs, [234] while immunotherapies have been developed to modulate 
the patient’s own immune cells to recognize and attack cancer cells. [235] However, these 
strategies are only effective against certain cancers and certain subtypes. As such, there is a 
great need for novel treatment strategies that can specifically target and infiltrate tumors 
thereby enhancing the efficacy of the delivered therapeutic while minimizing side effects.
To this end, it has been demonstrated that transplanted stem cells have the innate ability to 
home to tumors and metastases, enabling site-specific delivery. [236] The mechanisms that 
underlie stem cells tropism to tumors are far from understood; however, various chemokine–
chemokine receptor pairs have been associated with tumor tropism, with stromal cell-derived 
factor 1 (SDF1; also known as CXCL12) and its receptor CXC-chemokine receptor 4 
(CXCR4) being the most well studied. [237] As such, stem cells are attractive candidates that 
can act as delivery vehicles for the targeted treatment of tumors/metastases. To this end, 
unmodified stem cells have exhibited some intrinsic anti-tumor effects, which are attributed 
to the secretion of factors and physical interactions with tumor cells. [238] However, there 
have also been numerous conflicting reports suggesting that stem cells can actually protect 
cancer cells from immune recognition and treatment. [239] As such, to fully take advantage 
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of stem cells for cancer therapy, stem cells are being engineered to stably express or deliver 
various anticancer agents. In this way, they can act as delivery vehicles that specifically 
target and infiltrate tumors/metastases while circumventing the shortcomings that plague 
many conventional chemotherapeutic agents such as their short half-lives. In this section, we 
will highlight the progress that has been made in engineering stem cells for cancer. In 
particular, we will focus on the genetic modifications of stem cells as well as their use as 
delivery vehicles for gene therapies and other therapeutic molecules.
4.1. Stem Cell-Based Gene Therapy for the Treatment of Cancer
Recently, there has been increasing interest in the development of gene therapies as a unique 
strategy for the treatment of cancer. Gene therapy for cancer encompasses a wide range of 
treatments that have the common theme of delivering genetic materials (e.g., DNA, RNA, 
and RNA interference molecules) in order to modify cancer cells. [240] A wide variety of 
gene therapies have been tested on cancers including glioma, pancreatic cancer, lung cancer, 
liver cancer, and many more. Examples include the creation of cancer vaccines, targeting 
viruses to cancer cells for the induction of lysis and death, targeting supporting cells to 
cutoff the blood supply, and introducing genes into cancer cells that either cause death or 
restore them to a normal phenotype. [240] However, as with more conventional drugs, gene 
therapies are hampered by our current inability to specifically target them to the cancer. As 
such, combining the tumor tropism/targeting ability of stem cells with gene therapy 
strategies is a promising way to approach gene therapy thereby using stem cells as a delivery 
vehicle that can improve our ability to treat cancers. In this section, we will focus on two 
iterations of stem cell-based gene therapy for the treatment of cancer, which includes the use 
of engineered stem cells as a targeted delivery vehicle for gene therapies (e.g., using stem 
cells to deliver viruses) and genetically engineered stem cells to secrete therapeutic 
molecules for cancer therapy.
4.1.1. Engineering Stem Cells as a Delivering Vehicle for Gene Therapy—
Currently, one avenue of gene therapy that is being explored for the treatment of cancer is 
oncolytic viruses. Specifically, oncolytic viruses are viruses that are engineered to 
specifically replicate in and kill cancer cells while sparing healthy cells. [241] However, these 
viruses are quickly cleared through the bloodstream and may exhibit non-specific behaviors 
when directly administered. [242] Moreover, it has been demonstrated in clinical trials that 
engineered viruses often only affect tumor cells in close proximity to the site of injection, 
which significantly hampers its efficacy for metastases. [243] To address these issues, 
engineered stem cells that are loaded with oncolytic viruses can be used as effective targeted 
delivery vehicles for gene therapy. Due to their tumor-tropic properties, stem cells can carry 
the gene therapy vectors to tumors and sites of metastases thereby increasing the local 
concentration of therapeutic at the cancer site while decreasing the required dosage and 
subsequent side effects. [242]
To this end, multiple studies have shown that virus loaded stem cells can decrease tumor 
burden more effectively than direct viral injections. [244–246] In particular, MSCs have been 
the most frequently used stem cell source for this purpose with the most common 
demonstration being for gliomas. [246,247] For instance, Sonabed et al. demonstrated that 
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MSCs can effectively deliver oncolytic conditionally replicative adenovirus (CRAd) to 
glioma. [243] In particular, the promoter of CRAd’s were designed to be tumor specific and, 
in this case, are only activated at the tumor site by C-X-C chemokine receptor 4 (CXCR4), 
which has been shown to be overexpressed by gliomas. [248] To infect the MSCs with CRAd, 
cells were simply incubated with virus-containing medium (1000 viral particles per cell) for 
48 hours. It was found that CRAd-loaded MSCs effectively migrated in vitro and released 
CRAds that infected U87 glioma cells. More importantly, MSCs also migrated in vivo when 
injected away (5 mm) from the tumor site and delivered 46-fold more viral copies than 
CRAds injected alone.
Although the majority of studies using stem cells to deliver viruses have focused on MSCs, 
NSCs have also shown significant migratory ability for the treatment of gliomas. [12] As 
such, Ahmed and co-workers conducted a comparative study of NSC- and MSC-based 
carriers for oncolytic adenoviruses for GBM. [249] In this case, commercial stem cells were 
transduced with a variety of adenoviral vectors (AdWT, CRAd-CXCR4, etc.). Importantly, it 
was found that both cell sources had similar potential to function as cell carriers. However, 
the amount of virus released from NSCs was a log higher than from MSCs. As such, only 
virus loaded NSCs, which were administered intracranially to an orthotopic glioma model, 
significantly prolonged the survival of tumor bearing animals (68.7 days of survival for 
NSCs-injected animals vs 44 days for MSCs).
Besides glioma, Stoff-Khalili et al. implemented a therapy utilizing MSCs to shuttle CRAd 
agents to metastatic breast tumors. [250] In particular, the CRAd’s promoter was tumor 
specific and, as with the case in glioma, were also designed to be activated at the tumor site 
by CXCR4, which is overexpressed by certain breast cancer cell lines. [251] The MSCs were 
successfully loaded with the adenovirus via diffusion during 18 hours of incubation and 
were subsequently trypsinized and intravenously injected. Results indicated that mice 
bearing MDA-MB-231 breast cancer pulmonary metastases that were injected with the 
adenovirus loaded MSCs survived significantly longer than their control counterparts 
(approximately 3 times longer). [250] The ability of stem cells to infiltrate tumors was also 
hypothesized to significantly increase the tumor’s exposure time to the therapy resulting in 
the corresponding increase in therapeutic efficiency. [252]
Lastly, Mader and colleagues demonstrated the use of engineered patient-derived MSCs as a 
carrier to deliver oncolytic measles virus (MV) to ovarian tumors as optimization for a Phase 
I clinical trial. [253] In particular, various experimental models have previously validated the 
use of MV and phase I clinical trials are in progress to evaluate the safety and maximal 
tolerated dose of oncolytic MV for cancers such as ovarian cancer, myeloma, and glioma. 
[254]
 To further improve viral delivery to the tumor, the authors infected patient-derived 
MSCs with MV via centrifugation (70% infectivity with 1000 × g centrifugation for 5–10 
minutes), which did not compromise cell viability. In vivo, no tumors were seen despite 
receiving up to 1.6 × 10 9 MSCs/kg and MSCs did not promote the growth of SKOV3 
human ovarian cancer cells in mice. Using non-invasive SPECT-CT imaging, Mader et al. 
saw rapid co-localization of MV infected MSCs and SKOV3 tumors, within 5–8 minutes of 
intraperitoneal administration (Figure 12A). Importantly, MSCs could be pre-infected with 
MV, stored in liquid nitrogen, and thawed on the day of injection into mice without loss of 
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activity. Finally, it was found that MV infected MSC, but not virus alone, significantly 
prolonged the survival of animals bearing measles immune ovarian cancer (Figure 12B).
4.1.2. Genetically Engineering Stem Cells for Cancer Therapy—Aside from 
delivering oncolytic viruses to cancer, stem cells can also be genetically engineered to 
secrete: 1) therapeutic proteins or 2) enzymes that convert a separately administered non-
toxic prodrug into a cytotoxic drug. Using these approaches, engineered stem cells are 
capable of migrating to and continuously producing the drug or enzyme at the sites of cancer 
and metastases, thus bypassing restrictions such as the short half-life of drugs and the need 
for repeated drug dosages. [244] For this purpose, MSCs are, again, especially attractive as 
candidate carriers since they are relatively easy to expand and transduce. [255] Moreover, 
multiple studies have already shown that genetically engineered MSCs are efficient tools for 
delivering anticancer agents to metastatic tumors, as we will review later in this section. In 
particular, this section will focus on the use of genetically engineered stem cells for: 1) the 
secretion of therapeutic molecules and 2) the secretion of an enzyme that can then convert a 
separately administered prodrug.
4.1.2.1. Secretion of Therapeutic Proteins: When genetically engineering stem cells to 
secrete therapeutic proteins, there are a number of candidate genes including genes encoding 
proteins that directly act on malignant cells as well as those that affect supporting cells (e.g., 
blood vessel and stroma). This is typically achieved using viral methods, as although non-
viral vectors have been used and offer some advantages such as lower immunogenicity, they 
have a much lower efficiency. [256] In particular, direct effectors include cytokines such as 
interferon-β (IFN-β) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL). 
On the other hand, those that affect supporting cells typically target angiogenesis or induce 
an immune response via the secretion of interleukins.
In the case of IFN-β, high concentrations of IFN-β have been shown to inhibit cancer cell 
growth. However, the direct administration of IFN-β is limited by its short half-life and has 
been associated with excessive systemic toxicity. [257] Addressing these concerns, a number 
of studies have focused on using stem cells, especially MSCs, to deliver IFN-β specifically 
to tumors. [258] For instance, Studeny et al. engineered BM-derived MSCs to IFN-β via 
adenoviral transduction. [259] In vivo tests with mice carrying A375SM melanoma tumors 
demonstrated that the transplanted MSCs preferentially survive and proliferate in the 
presence of malignant cells and become incorporated into the tumor architecture as stromal 
fibroblasts. More importantly, the authors found that, on average, mice injected with 
engineered MSCs survived almost twice as long as control mice (60 days compared to 
control mice, which survived for only 37 days). On the other hand, the direct intravenous 
injection of recombinant IFN-β did not increase mice survival compared to control mice, 
which further supports the use of MSCs as a delivery vehicle for IFN-β. Similarly, Ren and 
colleagues reported that MSCs engineered with a recombinant adeno-associated virus 
encoding IFN-β could effectively treat prostate cancer lung metastasis. [260] Evaluation 30 
and 75 days after transplantation indicated a significant reduction in tumor volume. In 
addition, a significant increase in the natural kill cell activity was observed following stem 
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cell-based IFN-β therapy and systemic levels of IFN-β was not significantly elevated. Lastly, 
aside from MSCs, NSCs have also been used to deliver IFN-β but to a lesser extent. [261]
On the other hand, TRAIL has also been a cytokine of particular interest. TRAIL can induce 
apoptosis in a wide range of cancers while, generally, sparing normal healthy cells. [262] In 
particular, TRAIL has been shown to directly attach to death receptors (DR4 and DR5) that 
are preferentially expressed on tumor cells, activating pro-apoptotic proteases that result in 
cancer cell apoptosis. [263] However, translation of TRAIL into the clinic is confounded by 
its short half-life, inadequate delivery methods, and the fact that recent studies have found 
that TRAIL can cause some hepatotoxicity depending on the patient and drug combinations 
used. [264] As with IFN-β, MSCS have been shown to have the ability to deliver a secretable 
form of TRAIL, thereby enhancing the efficacy of TRAIL versus systemic administration of 
TRAIL alone. For example, engineered MSCs that secrete TRAIL have been utilized to treat 
in vivo glioma models. [265] In particular, these MSCs were transfected using a lentiviral 
vector and the resulting engineered MSCs secreted around 250 ng of TRAIL per every 
million cells over a 24-hour timespan. In addition, it was found that the engineered MSCs 
provided a method to facilitate the transportation of TRAIL across the BBB and continuous 
production of TRAIL helped mitigate the issue of TRAIL’s short half-life (Figure 13A).[266] 
Importantly, it was shown that MSCs were resistant to apoptosis from TRAIL making them 
viable targeting candidates. [265] As a result, the engineered MSCs exhibited significant anti-
tumor effect over unengineered MSCs resulting in a significant reduction in glioma burden 
via the induction of apoptosis and a significant decrease in the number of proliferating tumor 
cells (Figure 13).
Besides direct effectors of cancer apoptosis, stem cells have also been engineered to express 
indirect effectors such as molecules that inhibit the formation of the tumor-associated 
vasculature (TSP1 [267] or PEX) or immunomodulatory molecules (IL-12 and IL-18 [269]). In 
addition, the delivery of growth factor inhibitors such as NK4 using MSCs has also been 
shown to significantly increase survival of mice in a lung metastasis model. [270] For 
instance, Kim et al. engineered HB1.F3 immortalized NSCs to produce PEX in order to 
inhibit angiogenesis for the treatment of glioma. [271] In particular, PEX is a naturally 
occurring fragment of human metalloproteinase-2 and acts as an inhibitor of glioma and 
endothelial cell proliferation, migration, and angiogenesis. [272] Following transfection of 
the NSCs with a plasmid for PEX via SuperFect (Qiagen) and in vivo injection, histologic 
analysis showed that engineered NSCs migrated to the tumor boundary and caused a 90% 
reduction of tumor volume. In particular, this reduction was associated with a significant 
decrease in angiogenesis (44.8%) and proliferation (23.6%), demonstrating the effectiveness 
of engineering NSCs to express PEX.
Immunomodulatory molecules such as IL-12 are also effective for the treatment of cancer. 
Typically, immunotherapies focus on utilizing our own immune systems or its components 
to attack cancer cells. In particular, the delivery of cytokines such as IL-12 has been shown 
to boost both the innate and adaptive immune response against tumors. However, cytokines 
such as IL-12 are hindered by poor in vivo distribution and are associated with serious and 
even life-threatening consequences as well as marginal clinical responses in most patients. 
[273]
 To improve this, MSCs were transduced with an adenovirus expressing IL-12 and the 
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antitumor effect of these engineered MSCs, as injected via different routes, was evaluated in 
solid and metastatic melanoma. [274] As expected, it was reported that the engineered MSCs 
were more efficient than adenovirus alone as a cytokine gene delivery vehicle. Moreover, 
when comparing intratumoral, subcutaneous, and intravenous injection of engineered MSCs, 
intratumoral injection was found to be the best approach to induce a strong tumor-specific T-
cell response that correlated with anti-metastatic effects as well as the inhibition of solid 
tumor growth. Though, interestingly, intravenous injection of engineered MSCs actually 
induced earlier and higher peak levels of cytokines than other routes demonstrating that this 
is not an indicator of subsequent antitumor effects.
4.1.2.2. Secretion of Enzymes for the Conversion of Prodrugs: Prod-rugs are another 
viable candidate for stem cell delivery. Prod-rugs are compounds that are normally nontoxic. 
Instead, they are designed to respond to tumor specific enzymes, which then convert the 
prodrug into its toxic form. [275] Thus, prodrugs can provide a more targeted approach 
towards cancer therapy as greater concentrations of the cytotoxic form of the prodrug will be 
located at sites of cancer rather than in healthy tissues. [276] Moreover, prodrugs exhibit the 
bystander effect owing to the diffusion of the activated prodrug agent further enhancing the 
efficacy of the prodrug. [277] As such, three major suicide gene systems are currently used. 
Cytosine deaminase (CD) converts 5-fluorocytosine (5-FC) to the toxic antimetabolite 5-
fluorouracil. The herpes simplex virus thymidine kinase (HSV-tk) converts ganciclovir 
(GCV) to GCV-monophosphate, which is further phosphorylated to GCV-triphosphate 
thereby potently blocking DNA synthesis. Finally, carboxylesterase (CE) converts the 
prodrug irinotecan (CPT-11) to the potent topoisomerase inhibitor SN-38. [278]
While promising, the efficacy of prodrugs can be further improved using stem cell-based 
delivery thereby enhancing targeting and infiltrating. Moreover, an added benefit of stem 
cell-mediated prodrug delivery is that the stem cells are eliminated after conversion of the 
prodrug, thereby abolishing any concern over its long-term fate. Using the CD–5-FC system, 
engineered MSCs and NSCs have been shown to effectively treat tumors of the brain. 
[279–281]
 For instance, Aboody and colleagues engineered immortalized NB1.F3 NSCs to 
express CD via a retroviral vector for the treatment of glioblastoma (Figure 14A).[282] They 
found that these engineered NSCs retained their tumor tropism following intracerebral 
injection even in orthotopic glioblastoma bearing mice pretreated with radiation or 
dexamethasone, which mimics clinically relevant adjuvant therapies. Importantly, it was 
reported that the average tumor volume was one-third that of the average volume in control 
mice (Figure 14,C). Moreover, no toxicity associated with conversion of 5-fluorocyto-sine to 
5-fluorouracil was detected and there was no evidence of tumorigenesis attributable to the 
NSCs. Similarly, Wang and co-workers also engineered NB1-F3 cells to express CD and 
demonstrated their ability to target and disseminate therapeutic agent to medulloblastoma 
thereby resulting in a 76% reduction of tumor volume compared to unengineered controls. 
[283]
On the other hand, the HSV-tk system, which relies on the formation of gap junctions 
between the stem cell and surrounding target cells for an efficient bystander effect using the 
prodrug GCV, has shown efficacy in several cancer models including those of the brain, 
breast, and prostate. [284] For example, Yang and colleagues engineered iPSC-derived NSCs 
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using recombinant baculovirus vectors containing the herpes HSV-tk gene expression 
cassette to treat metastatic breast cancer. [280,285] In particular, they demonstrated that after 
tail vein injection, the engineered iPSC-derived NSCs displayed robust migratory capacity 
even outside the CNS in both immunodeficient and immunocompetent mice and homed in 
on established orthotopic 4T1 mouse mammary tumors. Moreover, the engineered iPSC-
derived NSCs were able to effectively inhibit the growth of orthotopic 4T1 breast tumors as 
well as the metastatic spread of the cancer cells, leading to prolonged survival of the tumor-
bearing mice (median survival of 39 days, which was significantly greater than controls) 
(Figure 14D,E).
Finally, NSCs engineered using the CE–CPT-11 system have proven to be effective in the 
treatment of preclinical models of brain, lung, and ovarian cancers. [286] For instance, Kim et 
al. engineered immortalized HB1.F3 NSCs to express CE using a retroviral vector to 
enhance the treatment of ovarian cancer. [283,287] In this study, the authors reported that the 
engineered NSCs retained their ability to migrate to ovarian tumors and greatly inhibited 
cancer cell proliferation. Interestingly, the authors compared engineered stem cells using the 
CD-5-FC system to engineered NSCs expressing CE for the CE-CPT-11 system and found 
that the CE approach seems to be more promising than the CD approach because the CE 
approach decreased proliferation with a lower engineered NSC cell number and at a lower 
concentration of CPT-11 when compared to the concentration of cells and prodrug needed 
for the CD approach.
4.2. Stem Cell-Based Drug Delivery
Finally, as mentioned previously, nanoparticle delivery systems are attractive for cancer drug 
delivery owing to their ability to carry high concentrations of often insoluble 
chemotherapeutic reagents, while protecting them from degradation by the harsh biological 
environment. [278] Furthermore, owing to the tunability of nanoparticles, their surfaces can 
be specifically modified to optimize properties such as stability, solubility, and targeting for 
cancer applications. [288] Despite the promise that nanotechnology holds for drug delivery, 
the use of nanoparticles in vivo and especially in the clinic have been confounded by serious 
limitations such as rapid clearance by the renal system, inefficient targeting and infiltration, 
and an inability to target micrometastases. [278,288] To this end, stem cell-based drug delivery 
for cancer therapy offers a unique strategy with which to overcome these barriers. [289] In 
particular, stem cells can be loaded with nanoparticles carrying the particular drug of interest 
and injected in vivo, where they can then specifically migrate to the tumor and its metastases 
and deposit the loaded nanoparticles in close proximity or within the tumor. Although 
seemingly straight forward, as with engineered stem cell therapies, the success of this 
strategy depends on the ability to load stem cells with nanoparticles without negatively 
affecting their migration capability and then efficiently release the nanoparticles and drugs 
once the engineered stem cells have reached the tumor or its metastases.
This field of research is still in a nascent stage with the earliest examples of engineering 
stem cells by loading them with nanoparticle being solely for tracking purposes. [290] For 
example, Loebinger and colleagues sought to monitor the tumor homing and infiltration 
capability of MSCs in vivo via MRI by engineering them with iron oxide MNPs. [291] To 
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this end, MSCs were first transfected with 200 nm MNPs in vitro with no observed effect on 
differentiation potential, proliferation, survival, or migration. The authors then showed that 
as few as 1000 MSCs carrying MNPs could be detected by MRI even one month after their 
coinjection with breast cancer cells that formed subcutaneous tumors. More importantly, 
Loebinger et al. found that i.v.-injected engineered MSCs could be tracked during their 
migration in vivo to lung metastases using MRI. Similarly, Gao and colleagues demonstrated 
that 500 nm core-shell fluorescent silica nanoparticle (C dots) could be retained in human 
MSCs for up to a month with minimal influence on MSC properties such as viability, 
proliferation, differentiation, and migration to tumors (e.g., breast tumors in zebra fish 
model). [292]
Building upon this, researchers have recently begun engineering stem cells with 
nanoparticles that are loaded with chemotherapies in order to achieve greater tumor targeting 
and infiltration over nanoparticle-based drug delivery methods alone. Towards this objective, 
one novel approach that was recently investigated involved loading the surface of MSCs 
with nanoparticles. [293] In particular, a 125 nm silica nanorattle–doxorubicin drug delivery 
system was efficiently anchored to MSCs by specific antibody–antigen recognitions at the 
cell membrane interface without the need for any MSC preconditioning (Figure 15). The 
MSCs could be loaded with up to 1500 nanoparticles while maintaining high cell viabilities 
as well as their tumor-tropic ability. Moreover, it was reported that the intracellular retention 
time of the silica nanorattle was no less than 48 h, which was a sufficient amount of time for 
the engineered MSCs to migrate to the U251 glioma tumors in vivo. Importantly, these in 
vivo studies demonstrated that the engineered MSCs could not only track U251 glioma cells 
more effectively than free DOX and nanoparticle-delivered DOX alone, but that the 
delivered DOX had a wider distribution and a longer retention time within tumor tissues. As 
a result, a significant enhancement in tumor-cell apoptosis and decrease in tumor burden was 
observed.
Lastly, another avenue of research that has engineered stem cells to carry nanoparticles is the 
use of the delivered nanoparticles for their other functionalities besides drug loading such as 
hyperthermia or photothermal therapy. For instance, Ruan et al. utilized fluorescent 
magnetic nanoparticle (FMNP)-labeled MSCs for the targeted imaging and hyperthermia 
therapy of in vivo gastric cancer. [294] In particular, the FMNPs consisted of MNPs and CdTe 
quantum dots embedded in an inert silica shell based on previously described methods from 
their lab. [295] Primary mouse marrow MSCs were then labeled with these amino-modified 
FMNPs and intravenously injected into a subcutaneous mouse model of gastric cancer. It 
was found the FMNPs remained attached to the MSCs for at least 14 days and that the 
engineered MSCs were able to retain their tumor targeting ability. Moreover, the engineered 
MSCs could be used to image in vivo gastric cancer cells even after being intravenously 
injected for 14 days. Once at the tumor, the engineered MSCs were exposed to an external 
alternating magnetic field thereby inducing magnetic hyperthermia from the embedded 
MNPs. In this way, the engineered MSCs significantly inhibited the growth of in vivo gastric 
cancer. Similarly, Schnarr and co-workers demonstrated that NSCs could also be loaded with 
gold nanoparticles, maintain their tumor tropism after engineering, and be used to ablate in 
vivo tumors via photothermal therapy. [296] As one can imagine, in future studies, these 
nanoparticles (e.g., MNPs and GNPs) can be loaded with a drug or other therapeutic 
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molecule, similar to what was demonstrated by Li et al. [293] and then delivered into stem 
cells thereby taking advantage of the multifunctionalities offered by nanoparticles for 
combined imaging, hyperthermia, and chemotherapy.
5. Engineering Stem Cells for Other Diseases
The development of engineered stem cell therapies for other diseases besides those 
discussed previously in this Review have primarily focused on autoimmune and other 
inherited diseases/disorders such as muscular dystrophy, Wiskott-Aldrich Syndrome, and 
leukodystrophies. In particular, the treatment strategies that have been developed for these 
diseases fall into two general categories: 1) use of engineered stem cells to deliver genetic 
material that can correct the inherent genetic defects or 2) engineering the stem cells ex vivo 
to correct the genetic defect and then reintroducing them back into the patient.
5.1. Muscular Dystrophy
Muscular dystrophy is a group of inherited disorders that are characterized by the 
degeneration of muscle, which leads to variable degrees of immobility such as confinement 
to a wheelchair and, in the most severe cases, weakness of the heart and/ or respiratory 
muscles thereby leading to premature death. [297] Many muscular dystrophies arise from 
loss-of-function mutations in genes encoding cytoskeletal and membrane proteins, with the 
most common and severe being Duchenne muscular dystrophy (DMD), which is caused by 
mutations in the gene encoding dystrophin. In particular, dystrophin is an integral part of a 
complex in muscle that links the intracellular cytoskeleton with the extracellular matrix and 
mutations in DMD causes the disassembly of the whole multiprotein complex leading to 
fragility of the sarcolemma. As a result, muscular dystrophies are some of the most difficult 
diseases to treat, as skeletal muscle is composed of large multinucleated fibers whose nuclei 
cannot divide.
To this end, three main therapeutic approaches are currently being pursued: 1) the 
introduction of genetic material (via viral or non-viral vectors) to repair the genetic 
mutation, 2) transplantation of dystrophin-positive cells, or 3) modulating the synthesis of 
endogenous gene products to make up for the mutation. In particular, the most promising 
approach consists of a combination of genetic and cellular therapy, wherein the patient’s 
own cells can be genetically engineered and then reintroduced back into the body. However, 
significant challenges remain as cell therapies would have to restore proper gene expression 
in hundreds of millions of postmitotic nuclei. [65] In this section, we will discuss the use of 
genetically engineered stem cells for muscular dystrophy as well as the use of engineered 
stem cells as a vehicle for genetic material.
5.1.1. Engineering Stem Cells by Genetic Modification for Muscular Dystrophy
—A number of studies have demonstrated that genetically engineered stem cells, which 
express genes that promote differentiation towards a muscle lineage or express the correct 
form of dystrophin, can be used to treat muscular dystrophy. As a proof-of-concept to 
demonstrate the utility of ESCs for skeletal muscle differentiation and eventual application 
to muscular dystrophy, Darabi and co-workers engineered ESCs to express Pax3 (Figure 16).
[298]
 In particular, Pax3 is a transcription factor, whose expression results in the activation of 
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myogenic regulatory factor (MRF) genes, Myf5, Myf6, MyoD1, and Myog. [299] Expression 
of Pax3 under a tetracycline transactivator in ESCs was achieved using Cre-lox. Following 
growth as embryoid bodies and exposure to doxycycline, cells from the engineered ESC 
conditions exhibited morphology resembling myogenic progenitors. This was confirmed by 
the upregulation of Pax3, Myf5 genes and, to a lesser extent, Myod1, and Myog as well as 
Myf5 and myosin heavy chain (MHC) (Figure 16B). Initial in vivo studies that sought to 
demonstrate the muscle regenerative potential of these engineered ESCs utilized a 
constitutive version of Pax3. Day 5 embryoid bodies, which demonstrated the greatest 
myogenic differentiation, were expanded, sorted for PDGF-α, a marker of paraxial 
mesoderm, and for the absence of Flk-1 (Figure 16A), and transplanted into cardiotoxin-
injured tibialis anterior muscles of mice lacking Rag2 and the common γ-chain of Fc 
receptors 24 hours after injury. When transplanted systemically or intramuscularly into 
cardiotoxin-injured immunodeficient or dystrophic mice, undifferentiated Pax3-induced 
myogenic progenitors demonstrated considerable potential for skeletal muscle regeneration 
by differentiating robustly into adult myofibers without the formation of teratomas. 
Regardless of the route of cell delivery, dystrophin restoration in the mdx mice (11–16% of 
total myofibers) was accompanied by a significant increase in contractile force (Figure 16C). 
These data demonstrate the therapeutic potential of ESCs in muscular dystrophy.
Similarly, Goncalves et al. recently engineered human MSCs to ectopically express full-
length dystrophin and demonstrated that these engineered MSCs can fuse with DMD 
myotubes thereby rescuing synthesis of full length dystrophin in DMD muscle cells. [300] To 
this end, they utilized a dual high-capacity adenovirus-adeno-associated virus hybrid vector. 
It was found that the engineered MSCs could participate in human myotube formation via 
cellular fusion when co-cultured with DMD myoblasts in an ex vivo culture model. More 
importantly, it was found that the engineered MSCs could rescue full length dystrophin 
synthesis in human dystrophin-defective myotubes.
5.1.2. Engineering Stem Cells to Deliver Genetic Materials for Muscular 
Dystrophy—A number of studies have also investigated engineering stem cells as delivery 
vehicles of genetic materials for the treatment DBD. For instance, Kazuki and colleagues 
reported a proof-of-concept study where they delivered the full-length dystrophin gene into 
iPSCs using a human artificial chromosome (HAC). [301] HACs can carry large genomic 
segments containing a whole genetic locus including the regulatory regions and microRNAs. 
Moreover, they can be engineered to express additional functional benefits and have the 
advantage of avoiding insertional mutagenesis as they do not become integrated into the host 
cell. [47] Specifically, Kazuki et al. demonstrated the complete correction of a genetic 
deficiency in iPSCs derived from DMD model (mdx) mice and human DBD patients using a 
HAC with a complete genomic dystrophic sequence (DYS-HAC) [302] via microcell-
mediated chromosome transfer (MMCT) (Figure 17).[303] Using this method, when 
transplanted in vivo, both DMD patient- and mdx-specific iPSCs with DYS-HAC were 
observed to form typical teratomas that differentiated into all three germ layers. Moreover, 
human dystrophin expression could be detected in muscle-like tissues. Lastly, chimeric mice 
from mdx-iPSCs (DYS-HAC) were produced and DYS-HAC was detected in all tissues 
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examined, with tissue-specific expression of dystrophin, which demonstrates the ability of 
patient-specific iPSCs and HAC to potentially treat DMD.
Advancing this strategy, Tedesco and colleagues demonstrated a modified application of the 
typical engineered stem cell strategy wherein the stem cells were used to transfer an artificial 
chromosome in order to correct the dystrophin mutation in DMD cells. [304] In this case, 
they developed a HAC vector containing the entire human dystrophin genetic locus that can 
be stably maintained in recipient cells. Specifically, Tedesco and co-workers first isolated 
mesoangioblasts from mdx dystrophic mice and subjected them to microcell-mediated 
chromosome transfer, which allowed for the introduction of the DYS-HAC vector. In vitro 
characterization of these engineered stem cells demonstrated that following transfer of 
cDNA encoding MyoD, engineered mesoangioblasts were induced to differentiate resulting 
in multinucleated myotubes that stained positive for MyoD and myosin heavy chain. 
Moreover, these cells underwent terminal skeletal muscle differentiation as demonstrated by 
the expression of myosin heavy chain and dystrophin. More importantly, following 
transplantation (three intramuscular injections into the tibialis anterior, gastrocnemius, and 
quadriceps every three weeks) of the engineered cells into severe combined immunodeficient 
(SCID)/mdx mice, muscles receiving injection with engineered cells exhibited extensive 
engraftment as well as large areas of dystrophin-positive fibers, which produced 25% of the 
amount of dystorphin produced by muscles of healthy control mice. Finally, morphometric 
analyses revealed a marked reduction in the fibrotic and cellular infiltrates of treated 
dystrophic muscles along with reduced necrosis and centrally nucleated muscle fibers 
indicating that treated muscles underwent fewer degeneration-regeneration cycles.
On the other hand, as DMD has been determined to be a hereditary disease that is caused by 
mutations that disrupt the dystrophin mRNA reading frame, it has been suggested that the 
forced exclusion (skipping) of a single exon may restore the reading frame. In particular, the 
majority of DMD mutations are localized in the central rod domain of the dystrophin where 
in-frame removal of central spectrin-like repeats has been demonstrated to conserve 
functionality. [305] With this in mind, Benchaouir et al. developed a combined exon-skipping 
and cell-based approach. This technology uses specific anti-sense oligonucletoides (AONs) 
that are designed to mask the putative splicing sites of exons in the mutated region of the 
primary RNA transcript. [306] For this purpose, blood- and muscle-derived CD133+ 
myogenic progenitors obtained from DMD patients, which exhibit a frameshifting deletion 
of exons 49 and 50 of dystrophin, were transduced with a lentiviral vector that harbored a 
cassette designed to favor skipping of exon 51 of the dystrophin mRNA. It was found that 14 
days after culture in myogenic conditions, both engineered CD133+ cell types (blood- and 
muscle-derived) generated full-length dystrophin mRNA and efficient exon-skipping was 
revealed. More importantly, these engineered CD133+ progenitors exhibited in vivo 
myogenic properties after implantation into the muscle of adult mouse recipients. For this 
experiment, 2 × 10 4 engineered cells were injected into the right transverse abdominis (TA) 
muscle of SCID/mdx mice. 21 and 45 days postinjection, the transplanted muscles were 
harvested and immunohistochemistry revealed that that transduced plasmid efficiently skips 
exon 51 of dystrophin. Finally, and most importantly, the authors demonstrated that intra-
arterial delivery of the engineered CD133+ cells could result in functional recovery of 
dystrophic mice wherein muscle function, as evaluated by tetanic force of isolated TA and 
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extensor digitorum longus (EDL) muscle, and in vivo treadmill exhaustion tests 
demonstrated that injection of engineered cells resulted in a significant increase in tetanic 
force and endurance capacity, respectively.
5.2. Wiskott-Aldrich Syndrome
Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency that is 
characterized by recurrent infections, microthrombocytopenia, eczema, autoimmunity, and 
an increased incidence of lymphoid malignancies. [307,308] It has been identified that WAS is 
caused by mutations in the WAS gene, which is exclusively expressed in hematopoietic 
cells. In particular, the WAS gene produces a WAS protein (WASP) that plays a key role in 
actin polymerization in hematopoietic cells, with domains involved in signaling, cell 
locomotion, and immunologic-synapse formation. [309,310] As such, WAS patients are 
characterized by an absence of WASP resulting in impairment of several immune cell 
functions such as leukocyte migration, [311] pathogen killing by natural killer cells and 
neutrophils, [312] antigen presentation by antigen-presenting cells, [313] homing of B cells, 
[314]
 and T-cell activation, which all lead to the above-mentioned effects. [315]
Owing to the wide range of hematopoietic cell types that are affected by WAS, therapeutic 
approaches have focused on HSCs. However, currently, the only absolute therapeutic option 
involves BM transplantation (BMT) from related human leukocyte antigen-identical or 
matched unrelated donors. [316] Moreover, owing to the lack of time, [317] patients lacking a 
related identical donor or a matched unrelated donor often have to undergo BMT from a 
mismatched related donor resulting in significant life-threatening risks such as the 
development of life-threatening Epstein-Barr virus lymphoproliferative syndrome, 
infections, autoimmunity, graft rejection, and graft-versus-host disease. [318]
To this end, an alternative therapeutic strategy involves the infusion of autologous HSCs that 
have been genetically engineered ex vivo to express the corrected WAS gene as these 
engineered HSCs would have a proliferative advantage over WASP-negative cells. [319] For 
instance, Marangoni et al. conducted the first long-term study wherein HSCs were 
engineered to express the corrected version of WAS. [320] This was accomplished using a 
human WAS promoter/cDNA encoding lentivirus to transduce lineage marker-depleted (lin
−) cells from BM BL6-was null mice. Transduced or control lin− cells were then injected into 
BL6-was null mice by sublethal irradiation and donor cell engraftment resulting in high and 
stable engraftment (69–100%) of all hematopoietic cell types for up to 12 months. 
Importantly, the authors observed a selective advantage for T and B lymphocytes expressing 
the transgenic WASP, improvement in B lymphocyte and platelet counts, as well as 
functional restorations such as T-cell receptor (TCR)-driven T-cell activation and B-cell’s 
ability to migrate in response to CXCL13. Finally, after long-term evaluation of safety, it 
was found that the use of engineered stem cells did not affect the lifespan of the treated 
animals.
Given the efficacy that engineered stem cells have shown in preclinical studies for the 
treatment of WAS, [307,321] clinical trials have recently been conducted. [322–324] For 
instance, Aiuti and co-workers tested their lentiviral method for engineering stem cells in 
clinical trials. In particular, to further improve the safety of engineered stem cells for WAS 
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treatment, Aiuti et al. developed a SIN lentiviral vector coding for human WASP under the 
control of a 1.6-kb reconstituted WAS gene promoter. [324] The use of this endogenous 
promoter combined with the SIN lentiviral vector ensured that the transgene was expressed 
in a physiological manner while reducing the risk of insertional mutagenesis. [309,325] In this 
phase I/II clinical trial, three children with WAS, as confirmed by genotyping and who did 
not have compatible allogenic donors, were enrolled. Autologous bone-marrow-derived 
CD34+ cells were collected, transduced twice with the lentiviral vector, [326] and rein-fused 
intravenously back into the patients 3 days after collection. All three WAS patients showed 
robust and multilineage engraftment (engraftment efficiency of 34%, 25%, and 48% for 
patient 1, 2, and 3, respectively) of the engineered HSCs in their BM and peripheral blood 
(PB), which was persistent for at least 30 months after therapy. In particular, WASP 
expression peaked in the first month after treatment and then stabilized. More importantly, 
all of the patients were clinically well during post-treatment follow-up of 20 to 32 months 
and showed substantial improvement in terms of WAS symptoms including resolution of 
eczema as well as decreases in the frequency and severity of infections. Moreover, platelet 
counts improved significantly during the first year, although they never returned to normal 
healthy levels. While serious adverse events did occur in patients 2 and 3 within the first 2 to 
6 months of gene therapy, they were mainly due to infection. Finally, no abnormal cellular 
expansion was detected in the PM and PB and lentiviral gene therapy did not induce 
selection of integrations near oncogenes.
Clinical trials have also been performed to test retroviral methods for engineering stem cells. 
In a study by Boztug and co-workers, two young boys, who were at least 12 months old and 
had been diagnosed with severe WAS (as documented by molecular and clinical phenotype), 
were treated with engineered HSCs expressing the corrected WAS gene. [322] To engineer 
the HSCs, autologous CD34+ HSCs were collected via leukopheresis. The cells were then 
transduced with a WASP-expressing retroviral vector. Following gene therapy, WASP-
positive cells in various leukocyte subgroups were detected by flow cytometry (increases in 
WASP-positive monocytes, lymphoid cells, and CD4+ and CD8+ T cells were seen 6 to 12 
months after gene therapy and remained stable). Moreover, an increase in platelet count was 
noted starting 6 to 9 months after gene therapy and stabilized even 2.5 years after gene 
therapy. Owing to these functional corrections owing to sustained WASP expression, the 
patients’ clinical condition markedly improved with resolution of hemorrhagic diathesis, 
eczema, autoimmunity, and predisposition to severe infection. Lastly, comprehensive 
insertion-site analysis showed vector integration that targeted multiple genes controlling 
growth and immunologic responses and despite targeting potential oncogenes, no persistent 
clonal imbalance had yet been observed at the time of the study.
Lastly, to test the long-term efficacy and genotoxicity, Braun et al., from the same group as 
Boztug, engineered HSCs using a retroviral vector to treat 10 patients with severe WAS. 
[323]
 In particular, peripheral blood mononuclear cells were harvested by leukapheresis upon 
treatment with recombinant human granulocyte colony-stimulating factor alone or in 
combination with the CXCR4 inhibitor plerixafor. Following reintroduction of the 
engineered cells, patients were followed for 1.5 to 6 years. High levels of engraftment were 
observed with a strong increase in the proportion of WASP-corrected lymphoid cells in all 
patients over time. All patients demonstrated significant increases in platelet counts after 
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gene therapy as well as improvements in lymphocyte number and function (Figure 18). 
However, clonality and insertion site analyses determined that retroviral insertion preferred 
gene loci within proto-oncogenes, where integration-driven overexpression led to the 
development of severe side effects such as leukemia. Specifically, seven patients developed 
acute leukemia (one acute myeloid leukemia (AML), four developed T cell acute 
lymphoblastic leukemia, and two developed primary T-ALL with secondary AML). 
Moreover, cytogenic analysis revealed additional genetic alterations such as chromosomal 
translocations. As such, while engineered HSCs show great promise for WAS treatment, 
retroviral transduction is associated with long-term toxicity.
Overall, these findings demonstrate the great potential that engineered stem cells hold for the 
treatment of WAS. Owing to the selective advantage that WAS-corrected HSCs have over 
WAS-negative HSCs, they are able to graft and repopulate various hematopoietic cell types. 
As such, WAS symptoms are ameliorated, which has been confirmed in clinical trials. 
However, it is also clear that the method of engineered stem cells is critical to maximize 
long-term efficacy and genotoxicity. Studies using lentiviral vectors have demonstrated good 
safety but long-term studies using retroviruses resulted in the development of acute leukemia 
as well as additional genetic alterations such as chromosomal translocations. While more 
long-term follow-up using lentiviral vectors remains to be conducted, it appears that 
lentiviral methods are more suitable for engineering HSCs for WAS treatment.
5.3. Leukodystrophies
Lastly, leukodystrophies are a group of genetic diseases that are characterized by white 
matter deterioration and typically manifest during childhood or adolescence. In particular, 
leukodystrophies result in the degeneration of myelin sheaths in the CNS and sometimes in 
the peripheral nerves owing to defects in the synthesis and maintenance of the myelin 
membrane. Overall, most leukodystrophies fall into one of three categories: 1) lysosomsal 
storage diseases, 2) peroxisomal diseases, and 3) diseases caused by mitochondrial 
dysfunction. [327] As a result of this deterioration, clinical regression of skills are observed 
and in the most severe cases, neurological devastation leading to premature death. [328]
Currently, there are no available curative treatments for leukodystrophies and therapy is only 
supportive. [329] Various dietary regimens and pharmacological agents have not had a 
favorable effect on the clinical course of the disease nor its associated biochemical 
abnormalities. Moreover, while HSC transplantation (HSCT) can be effective in early stage 
leukodystrophies, it has proved to be ineffective in children with the late infantile disease 
and generally in all patients with evident neuropsychological and/or neurological signs. [330] 
On the other hand, enzyme replacement therapy has shown some efficacy but is faced by 
significant limitations such as the BBB and the fact that lifelong administration would be 
required. As such, owing to the migratory ability of stem cells as well as their ability to be 
engineered with various genes, efforts have focused on improving the efficiency of 
transduction to use these engineered stem cells to replace dysfunctional cells and to deliver 
the corrected enzyme.
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5.3.1. Metachromatic Leukodystrophy—Metachromatic leukodystrophy (MLD) is a 
neurodegenerative lysosomal storage diseases caused by an arylsulfatase A (ARSA) 
deficiency. This enzymatic defect results in the accumulation of the ARSA substrate, 
galactosylceramide I 3-sulfate (sulfatide), which is a major sphingolipid of myelin, in 
oligodendrocytes, microglia, and certain neurons of the CNS as well as Schwann cells and 
macrophages of the PNS. This build up induces widespread demyelination and 
neurodegeneration and as a result, children affected by MLD display progressive neurologic 
symptoms, including ataxia, seizures, and quadriplegia, culminating in decerebration and 
eventual death. [329]
As mentioned previously, HSCT has seen limited effectiveness while protein replacement 
faces serious barriers (e.g., BBB). Previous studies have engineered HSCs to express ARSA. 
However, they were only used to prevent the development of major disease manifestations in 
mice treated at the pre-symptomatic stage. While this was promising, in most clinical cases, 
unless a family history is available, the diagnosis of MLD is made after the onset of 
symptoms. [331] To address this issue, Biffi and colleagues engineered hematopoietic stem 
progenitor cells (HSPCs) to overexpress ARSA via lentiviral transduction in order to treat 
MLD after symptoms have already been observed. [332] HSPCs from ARSA-negative donors 
were transduced with lentivirus vectors expressing either ARSA or GFP. These cells were 
then transplanted into a mouse model of MLD that was generated by targeted disruption of 
the murine ARSA gene. [333] The authors found that the HSC gene therapy could reverse 
neurological deficits and neuropathological damage in affected mice (Figure 19). However, 
the efficacy of engineered stem cells was dependent on ARSA overexpression in microglia 
progeny of transplanted HSPCs or, in other words, microglia were found to be primarily 
responsible for ARSA bioavailability in the CNS. On the other hand, a peripheral source of 
enzyme, as established by transplanting ARSA-overexpressing hepatocytes from transgenic 
donors, failed to effectively deliver the enzyme to the CNS further demonstrating the 
importance of microglia progeny.
Given their promising preclinical results, Biffi and co-workers recently performed a phase 
I/II clinical trial in three presymptomatic MLD patients that were biochemically 
characterized for ARSA deficiency. [334] To perform this study, Biffi et al. first optimized the 
lentiviral-mediated gene transfer of ARSA under the control of the human phosphoglycerate 
kinase promoter in human HSCs. To this end, transduction of human BM-derived CD34+ 
cells were optimized to reach ≥2 vector copy number per genome based on the ARSA 
overexpression levels that are required for therapeutic efficacy. [335] As a result of this 
optimization, a vector copy number to genome ratio of 2.5 to 4.4 was achieved and the 
transduction efficiency was found to be 90 to 97%. For transplantation, a myeloablative 
busulfan regimen was administered intravenously to the patients in 14 doses over 4 days 
prior to cell transplantation. The authors found a high-level of stably engrafted engineered 
stem cells in the BM and peripheral blood of all patients with 45 to 80% of BM-derived 
hematopoietic colonies harboring the vector. As a result, ARSA levels were reconstituted to 
above normal values. Importantly, the disease did not progress in any of the treated patients 
and analysis of the lentiviral integration demonstrated that there was no evidence of aberrant 
clonal behavior.
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These results suggest that engineering HSCs with ARSA can effectively treat MLD patients 
when therapy begins at both the asymptomatic and symptomatic phases of their disease. In 
particular, engineered HSCs can correct already established neurologic disease 
manifestations and neuronal damage when applied to symptomatic MLD mice.
5.3.2. X-Linked Adrenoleukodystrophy—As opposed to MLD, which is a lysosomal 
storage disease, X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disease. X-ALD 
is caused by a mutation in the ABCD1 gene, which encodes a transporter (ALD protein) that 
is localized in the peroxisomal membrane and is involved in the metabolism of very-long-
chain fatty acids (VLCFA). Deficiency in the ALD protein leads to the accumulation of 
VLCFA and progressive demyelination in the CNS. X-ALD typically affects boys between 
the ages of 5 and 12 and leads to a vegetative state or death within 2–5 years. [336]
Currently, HSCT is the only effective therapy, provided that it is performed at an early stage, 
as once the disease progresses, demyelination cannot be arrested. [337] However, owing to 
the donor-related constraints and the fact that it carries considerable risk of mortality, 
engineered HSCs may provide an appropriate therapeutic alterative. To this end, studies have 
demonstrated that lentiviral transduced human ALD CD34+ cells can be transplanted into 
nonobese diabetic (NOD)/SCID mice for the treatment of X-ALD. The recipient mice 
showed in vivo expression of ALD protein in human monocytes and macrophages derived 
from engrafted human stem cells. [338] More importantly, human BM–derived cells were 
shown to migrate into the brain of recipient mice and then differentiate into microglia 
expressing the human ALD protein. [339]
Owing to this promising preclinical data, Cartier et al. engineered HSCs using a lentiviral 
vector encoding wild-type ABCD1 in a clinical trial with X-ALD patients. [340] In particular, 
the study enrolled two X-ALD patients who had progressive cerebral demyelination and 
adrenal insufficiency and who had no human leukocyte antigen (HLA)-matched donor or 
cord blood for allogeneic HCT. CD34+ cells were removed from these patients, genetically 
corrected ex vivo, and then re-infused into the patients after they received a full 
myeloablative treatment to increase the engraftment of transduced HSCs as lentiviral 
correction of ALD HSCs does not provide a selective growth advantage. Following 
transplantation, 50% and 33% of CD34+ cells expressed the ALD protein 5 days after 
transduction in patient 1 and 2, respectively. Moreover, VLCFA levels in transduced CD34+ 
cells was reduced by 55% and 68% in patient 1 and 2, respectively. Hematopoietic recovery 
occurred at days 13 to 15 following transplantation and plateaued thereafter. Over a span of 
24 to 30 months of follow-up, polyclonal reconstitution was detected, with 9 to 14% of 
granulocytes, monocytes, and T and B lymphocytes expressing the ALD protein. These 
results strongly suggest that HSCs were transduced in the patients. Beginning 14 to 16 
months after infusion of the genetically corrected cells, progressive cerebral demyelination 
in the two patients stopped, a clinical outcome comparable to that achieved by allogeneic 
HCT (Figure 20). Finally, genome-wide monitoring of lentivirus-marked HSC clonality in 
the patients determined that no obvious clonal skewing or dominance in hematopoiesis 
existed, though a longer follow-up with a larger sample size is needed to verify the safety of 
this strategy. [341]
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6. Conclusion
In this Review, we discussed the use of engineered stems for various biomedical 
applications. In particular, in addition to briefly covering the available cell sources and 
strategies that have been developed to engineer stem cells, we systematically reviewed the 
application of engineered stem cells to tissue regeneration (e.g., nervous, bone, cartilage, and 
cardiac tissue), the treatment of immunodeficiency diseases (e.g., muscular dystrophy, 
Wiskott-Aldrich Syndrome, and leukodystrophies), and cancer.
In terms of future perspectives, while engineered stem cells have shown great potential and 
success in preclinical and clinical studies for various biomedical applications such as tissue 
regeneration as well as for the treatment of genetic diseases and even for cancer, there is still 
a long way to go before we witness their widespread use in the clinic. In particular, there are 
two major limitations that must be overcome before this can become a reality. First, stem 
cell therapies have not yet been embraced in the clinic, as we still do not have a deep 
biological understanding of what these cells are. For instance, even reaching a consensus on 
the precise characteristics of a given type of stem cells remains a challenge. [342] The second 
barrier is in the use of gene therapies, which remains a great technical challenge. 
Specifically, it is very difficult to introduce new genetic materials (e.g., DNA, RNA, RNAi) 
into cells without causing detrimental side effects (e.g., tumorigenesis from integration of 
viral DNA into the host genome). As such, before engineered stem cell therapies can reach 
their full potential, stem cell and gene therapies must first, separately, prove to be safe and 
efficient.
To this end, there have recently been promising technological breakthroughs that could have 
a significant effect on our ability to engineer stem cells. The CRISPR/Cas gene-editing 
technology is one of these breakthroughs. In particular, CRISPR stands for clustered 
regularly interspaced short palindromic repeats, which are associated with RNA-guided 
nucleases such as Cas9 genes, hence their name (CRISPR/Cas). This system was developed 
for gene editing in 2013 and is generally used by delivering the Cas9 protein (either protein 
or plasmid) and appropriate guide RNAs (for a particular targeted site of the host genome) 
into the target cell resulting in the desired alteration of the genome (e.g., point mutations, 
insertion, etc.). [343] Current demonstrations have focused on modeling diseases such as 
cancer. [344] However, a few studies have moved beyond proof-of-concept studies to show 
the utility of CRISPR/Cas systems. For instance, Long and colleagues recently utilized 
CRISPR/Cas9 to edit the germline of mice thereby preventing the development of muscular 
dystrophy. [345]
Besides further developing our understanding of stem cells and gene therapies as well as 
applying new techniques to more precisely engineer stem cells, engineering stem cell 
approaches can also be enhanced by improving stem cell efficacy. For instance, the 
modification of stem cells with genes that enhance survival was briefly discussed in this 
review for cardiac regeneration. [146] However, in addition to this approach, other 
researchers have focused on enhancing stem cell migration (e.g., to tumors) via the 
overexpression of chemokine receptors such as CXCR. [346] Finally, strategies aimed at 
inducing cell lysis or apoptosis of the engineered stem cells once they have performed their 
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role are also under investigation. An example of this was briefly discussed previously with 
regard to the use of prodrug systems with engineered stem cells for the treatment of cancer. 
[282]
 As such, there is significant room to develop and improve engineered stem cell 
approaches.
In conclusion, although it will be a long time before we see the full impact that engineered 
stem cells can have in the clinic, as evidenced by the preclinical and clinical studies that 
have been conducted up till now, engineered stem cells will ultimately offer tremendous 
promise for various biomedical applications. We hope that this article has inspired interest 
from researchers in various disciplines, whose interdisciplinary cooperation will be required 
to push engineered stem cells into the clinic.
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chemical functional genomics to modulate signaling pathways in cells (e.g., stem cells and 
cancer cells) towards specific cell lineages or behaviors.
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Figure 1. 
Engineering stem cells for biomedical applications. Stem cells can be obtained from various 
sources, engineered using viral and non-viral methods, and then reintroduced back into the 
patients’ body. These engineered stem cells can take on a number of forms. For instance, 
engineered stem cells encompass the genetic modification of stem cells as well as the use of 
stem cells for gene delivery, nanoparticle delivery and loading, and even small molecule 
drug delivery. Reproduced with permission.[347] Copyright 2012, Nature.
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Figure 2. 
Engineering mesenchymal stem cells to express MNTS1 to enhance the treatment of spinal 
cord injury. A,C,E,G) Representative micrographs of rat spinal cord sections (axial) 1000 
μm rostral to the epicenter of the insult. Sections were stained by hematoxylin and eosin and 
luxol fast blue. Scale bar: 500 μm. Both transplanted MSCs and engineered MSCs 
demonstrated reduced cavity size following SCI. However, only engineered MSCs promoted 
axonal growth and angiogenesis while decreasing inflammation. B,D,F,H) 3D reconstruction 
of injury in B) control, D) MSCs, F) engineered MSCs expressing MNTS1, and H) 
engineered MSCs expressing mutated MNTS1 with reduced binding to p75NTR. Reproduced 
with permission.[112] 2013, Elsevier.
Yin et al. Page 67
Adv Healthc Mater. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Engineered cells expressing nerve growth factor can help reverse Alzheimer’s disease in 
patients. Averaged FDG PET scans in four subjects treated with NGF, overlaid on 
standardized MRI templates. Representative axial sections, with 6–8 months between the 
first and second scan, showing widespread increases in brain metabolism. Flame scale 
indicates FDG use/100 g tissue/min; red color indicates more FDG use than blue color. 
Reproduced with permission.[127] Copyright 2005, Nature.
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Figure 4. 
Engineered neural stem cells co-transfected with Nurr1 and Brn4 significantly increases the 
maturity and viability of dopaminergic neurons and reverses behavioral deficits in 
Parkinsonion rats. A) HPLC quantification of dopamine (DA) release in the different groups. 
*p < 0.01 compared with sham group, #p < 0.01 compared with Nurr1 group, p < 0.01 
compared with Nurr1 + Brn4 group, n = 6. B) Rotation behavioral analysis induced by 
apomorphine after NSC transplantation in all groups. *p < 0.01 compared with sham group, 
#p < 0.01 compared with Nurr1 group, n = 12. Reproduced with permission.[138] Copyright 
2013, Elsevier.
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Figure 5. 
Engineered bone marrow-derived mesenchymal stem cells expressing hepatocyte growth 
factor are more therapeutically efficient than mesenchymal stem cell therapy alone for the 
treatment of stroke. A,B) Reduction of infarction areas on days 3 and 14 of groups 1, 2, and 
4, which received transplantation 2 h after MCAO occurred: coronal sections were stained 
with TTC. The red region shows the intact area while the white region shows the infarction 
area. C,D) Quantification of % CIV in the hemispheric lesion area on days 3 and 14. 
Treatment was given at 2 and 24 h after ischemia. Data are presented as means ± standard 
deviation. (p < 0.05; < 0.01). n = 6 for groups 1, 2, 4, and n = 5 for groups 5 to 7 at each 
time point. Reproduced with permission.[144] Copyright 2006, Elsevier.
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Figure 6. 
“Same day” strategy wherein stem cells are engineered with BMP-2 to enhance bone repair. 
Steps involved in the “same day” ex vivo gene therapy. A) Harvest bone marrow from rat 
femur; B) Ficoll separation and preparation of “same day” rat bone marrow cells (SD-
RBMCs) for viral transduction (time required = 0.5 h); C) Short-duration viral transduction 
of SD-RBMCs (time required = 1 h); D) Post-transduction preparation of SD-RBMCs (time 
required = 1 h); E) Placement of transduced SD-RBMCs on a collagen-ceramic matrix and 
implantation into the femoral defect. F) Representative images of healed femoral defects in 
animals treated with transduced SD-RBMCs. Double white arrows depict bridging bone 
across the femoral defect and restoration of cortex. G) Femoral defects treated with 
transduced cultured bone marrow cells (C-RBMCs) also exhibited healing. Defects treated 
with H) nontransduced SD-RBMCs, I) nontransduced C-RBMCs, and J) carrier alone 
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demonstrated some bone formation but none exhibited complete healing. Reproduced with 
permission.[163] Copyright 2011, Nature.
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Figure 7. 
Engineered adipose stem cells expressing the SOX trio in combination with a PLGA 
scaffold enhances chondrogenesis for cartilage regeneration. A) Gross findings from defects 
implanted with PLGA scaffold only (group 1), implanted with ASCs/PLGA scaffold (group 
2), implanted with ASC/SOX trio pDNA-incorporated PLGA scaffold (group 3); B) The 
ICRS macroscopic score; C) Histological findings; D) and O’Driscoll scores. n = 4, *p < 
0.05. Reproduced with permission.[181] Copyright 2011, Elsevier.
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Figure 8. 
Engineered stem cells expressing TGF-β3 combined with scaffold for cartilage repair. A) 
Scanning electron micrograph showing the architecture of the 3D orthogonal woven PCL 
scaffold. (Scale bar, 500 μm). B) Fluorescence microscopy from iLVT constructs after 28 
days in chondrogenic culture. C,D) Quantification of cartilaginous ECM components in the 
nontransduced (NT), rhTGF-β3 (rhT), and immobilized lentiviral TGF (iLVT) groups. 
Sulfated glycosaminoglycan content and total collagen content were normalized to DNA 
content. Bars represent means ± SEM (n = 6). Groups not sharing the same letter or symbol 
are statistically different (p < 0.05). Reproduced with permission.[185] Copyright 2014, 
PNAS.
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Figure 9. 
Engineering stem cells via the co-delivery of Cbfa-1-targeting siRNA and SOX9 protein 
using PLGA nanoparticles for cartilage regeneration. Schematic showing SOX9 protein 
encapsulated by biodegradable PLGA nanoparticles and complexed with Cbfa-1-targeting 
siRNA for the induction of chondrogenesis in human mesenchymal stem cells. Reproduced 
with permission.[188] Copyright 2014, Elsevier.
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Figure 10. 
Engineering mesenchymal stem cells with angiogenin to enhance cardiac repair. Effects of 
angiogenin modified MSC transplantation on heart remodeling. A) Transverse sections of 
hearts treated with MSC-AdANG, with MSC-AdEGFP, and with PBS were HE stained. C) 
Smaller infarct sizes and D) LV chamber sizes as well as E) thicker border-zone walls were 
seen in the post-MI heart treated with MSC-AdANG compared with control hearts. Collagen 
in the infarct areas was shown by VG staining. B,F) Positively stained fibrous infarct areas 
were clearly observed in the PBS group, and not obviously reduced in MSC-AdEGFP group, 
but significantly reduced in MSC-AdANG group. Reproduced with permission.[215] 
Copyright 2008, Elsevier.
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Figure 11. 
Engineering stem cells to achieve optogenetic control of heart muscle. Expression and 
function of ChR2 in ventricular cardiomyocytes from CAG-ChR2 mice. A) Fluorescence 
image of the native membrane-bound ChR2-EYFP signal (green) overlaid with α-actinin 
immunostaining (red) in cardiomyocytes of the ventricle and colocalization with the t-
tubulus system (inset). Nuclei are shown in blue. Scale bars, 20 μm. B) Inward currents 
evoked at a holding potential of −40 mV by light stimulation at 0.09, 0.18, 0.45 and 1.75 
mW mm−2 (from top to bottom). Monoexponential fit to measure the time constant of decay 
is shown in red. pA, picoampere; pF, picofarad. C) Repetitive action potential generation by 
1-ms light pulses (blue bars) of 0.91 mW mm−2. D) Action potential generation by light 
pulses (10 ms; light blue line) of different intensities in a representative single cell. 
Reproduced with permission.[228] Copyright 2010, Nature.
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Figure 12. 
Mesenchymal stem cells as virus carriers for the treatment of ovarian cancer. A) MSCs 
labeled with DiR and infected with measles virus expressing RFP (MV-RFP) were injected 
into mice bearing SKOV3ip.1 tumors that stably expressed CFP. Representative images from 
mice that received MSCs from healthy donors (MSC 493B) or ovarian cancer patients (FB8) 
showed co-localization of MV-infected MSCs with the tumors. B) Mice with SKOV3ip.1 
tumors were passively immunized with measles immune human sera and given 105 TCID50 
MV-NIS or 105 MV-NIS infected MSCs at 7 days post-tumor implantation. RT = MSCs 
were given 20 Gy radiation immediately before MV-NIS infection. F/T = Frozen stock of 
MV infected MSCs were thawed, washed, and used immediately. Reproduced with 
permission.[253] Copyright 2013, BioMed Central.
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Figure 13. 
Mesenchymal stem cells genetically engineered to secrete TRAIL to enhance the treatment 
of glioma. A–F) Serial in vivo bioluminescence imaging of tumor growth following 
intracranial implantation of Gli36-EGFRvIII-FD glioma cells mixed with MSCs expressing 
S-TRAIL (MSC-S-TRAIL; B,D,F) or GFP (MSC-GFP; A,C,E). G) Relative mean 
bioluminescent signal intensities after quantification of in vivo images. H–M) 
Photomicrographs show the presence of cleaved caspase-3 (H) and Ki67-positive cells (K) in 
brain sections from MSC-S-TRAIL-treated and control mice (I,L) 6 days after implantation. 
Plot shows the number of cleaved caspase-3 (J) and Ki67 (M) cells in MSC-S-TRAIL and 
MSC-GFP-treated tumors. (Green, MSCs; red, glioma cells; purple, Ki67 or cleaved 
caspase-3 expression). Reproduced with permission.[265] Copyright 2009, PNAS.
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Figure 14. 
Engineering stem cells to secrete enzymes for the conversion of prodrugs. A) Diagram of 
CD-expressing NSCs localized to tumor cells, and CD conversion of 5-FC to 5-FU, which 
readily diffuses out of the NSCs to selectively kill the surrounding tumor cells. B,C) H&E-
stained brain tumor sections from U251 glioma–bearing mice that received HB1.F3.CD 
NSCs only (B) or HB1.F3.CD NSCs in combination with 5-FC (C). White arrows indicate 
tumor region. Reproduced with permission.[282] Copyright 2013, Science. D) Brain injection 
of NSC1-tk cells coupled with GCV treatment prolonged the life of mice inoculated with 
U87 glioma cells. Statistical analysis was performed using the log rank test. E) 
Representative pictures of brain sections show the tumor size of different groups. NSC1-tk 
brain injection followed by GCV i.p. injection appears to shrink the tumor. Reproduced with 
permission.[280] Copyright 2012, Nature.
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Figure 15. 
Engineering mesenchymal stem cells with silica nanorattle-doxorubicin for glioma therapy. 
General scheme of silica nanorattle-doxorubicin-anchored MSCs for tumor-tropic therapy. 
Reproduced with permission.[293] Copyright 2011, ACS.
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Figure 16. 
Engineering embryonic stem cells with Pax3 to induce differentiation to skeletal muscle for 
the treatment of muscular dystrophy. A) Doxycyline-induced cell monolayers resulting from 
PDGF-αR+Flk-1− sorted cells from day 5 embryoid bodies were transplanted by various 
routes of administration (i.m., i.v. and i.a.) into Rag2−/−γc−/− immunodeficient mice or mdx 
mice (with or without cardiotoxin (CTX) pre-injury). B) Analyses of Rag2−/−γc−/− mice 
(pre-injured with cardiotoxin) 30 d after i.m. transplantation (n = 8 mice). Shown is 
immunostaining for GFP (green) and MHC (red). Top and bottom rows show different 
magnifications. Scale bars, 100 μm. C) Performance on the rotarod was assessed in mdx 
mice pre-injured with cardiotoxin (both legs) and treated with PBS (control, blue) or i.v. cell 
transplantation (red). B/6 mice (green) also pre-injured with cardiotoxin (both legs) were 
analyzed as a reference. *p < 0.05. Reproduced with permission.[298] Copyright 2008, 
Nature.
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Figure 17. 
Engineering stem cells to deliver human artificial chromosomes for the treatment of 
muscular dystrophy. The scheme illustrates the various steps of the process. 
Mesoangioblasts were first isolated from mdx dystrophic mice (1) and transduced with the 
DYS-HAC vector (shown in the upper part of the panel) (2); they then underwent selection. 
Selected clones (EGFP-positive) were transduced with two lentiviral vectors expressing 
MyoD and nLacZ (3). After in vitro characterization (4), the corrected mesoangioblasts were 
transplanted into dystrophic SCID/mdx mice (5). Afterwards, the mice were analyzed for 
dystrophin expression and morphological and functional recovery (6). MABs, 
mesoangioblasts; mdx (DYS-HAC) MABs, DYS-HAC–corrected mdx-derived 
mesoangioblasts; MMCT, microcell-mediated chromosome transfer; EGFP, enhanced green 
fluorescent protein; mDys, murine dystrophin; hDys, human dystrophin. Reproduced with 
permission.[304] Copyright 2011, Science.
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Figure 18. 
Stem cell gene therapy for Wiskott-Aldrich Syndrome. A) Platelet counts were assessed 
before GT, at 12 months after GT, and at 24 and 36 months after GT. Wilcoxon matched-
pairs signed rank test was used to assess significance levels. B) Statistical analysis of NKIS 
formation estimated by confocal microscopy for healthy donors (HD, n = 8), for WAS 
patients before GT (n = 8), and for WAS patients after GT (n = 8). C) PB IgE levels are 
shown at different time points after GT. D) Colonoscopy pictures of patient WAS9 before 
and after GT (arrows indicate areas of inflammation). Reproduced with permission.[323] 
Copyright 2014, Science.
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Figure 19. 
Engineering hematopoietic stem cells to express ARSA for the treatment of metachromatic 
leukodystrophy. A,B) GMFM score (A) and NCV index (B) of the three treated patients and 
of a historical cohort of LI-MLD patients (gray circles). The dotted lines indicate (inset, 
color code) the expected time of disease onset, according to the onset observed in their 
affected matched siblings; n.r., normal range of the NCV index. C) Axial T2 weighted fast 
spin-echo MR images (top) and FLAIR MR images (bottom) obtained from patient MLD01 
at baseline (before GT) and at +2 years after treatment, and corresponding (equivalent) 
images of an age-matched untreated patient with LI-MLD (in parenthesis, the chronological 
age at imaging acquisition in months). Reproduced with permission.[334] Copyright 2013, 
Science.
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Figure 20. 
Engineering hematopoietic stem cell with ABCD1 to enhance the treatment of X-Linked 
Adrenoleukodystrophy. Brain MRIs from A) P1 and B) P2 before and after gene therapy. C) 
Progression of cerebral demyelinating lesions in an untreated 8-year-old ALD patient. 
Reproduced with permission.[340] Copyright 2009, Science.
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Table 1
Stem Cell Sources
Name Sources Advantages Disadvantages
Neural Stem Cells Brain and spinal cord 1. Multipotent: can differentiate into 
neurons, astrocytes, and 
oligodendrocytes
1. Limited differentiation potential
2. Show tumor-tropic properties for 
various cancers
2. Limited source
Hematopoietic Stem Cells Bone marrow, cord 
blood, peripheral 
blood
1. Multipotent: can form lymphoid 
and myeloid blood cells
2. Many sources
3. Most well-established stem cell 
source
Limited differentiation potential
Mesenchymal Stem Cells Bone marrow, 
adipose tissue, cord 
blood
1. Multipotent – readily differentiates 
into bone, cartilage, fat, and muscle 
but can also be induced to 
differentiate into neuronal cells
1. Limited differentiation potential but 
better than NSCs and HSCs
2. Many sources 2. Immunosuppressive properties
Embryonic Stem Cells Inner cell mass of 
blastocyst
Pluripotent – has the highest 
differentiation potential
1. Ethically controversial source 
(destruction of embryos)
2. Teratoma formation in vivo (requires ex 
vivo differentiation prior to transplantation)
Induced Pluripotent Stem 
Cells
Somatic cells 1. Pluripotent: has similar 
differentiation potential as ESCs
1. Potential tumorigenicity
2. Can be derived from many cell 
types
2. Low reprogramming efficiency
3. Patient-specific 3. Characteristics are protocol dependent
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Table 2
Viral Delivery Methods.
Feature Retroviral Vector Lentiviral Vector Adenoviral Vector Adeno-Associated Viral Vectors
Particle size (nm) 100 nm 100 80–120 20–30
Genetic material ssRNA (positive strand) ssRNA (positive strand) dsDNA ssDNA
Cloning capacity (Kb) 7–8 7–9 Up to 36 ≈2.4–4
Chromosomal Integration Yes Yes No Yes (in about 1–10% of infected 
cells)
Immune response induction Moderate Low Moderate–High 
(due to large size)
Low
Comments: Low titers and can only 
primarily infect 
dividing cells
High efficiency and can 
infect both dividing and 
nondividing cells
High transduction 
efficiency in both 
dividing and 
nondividing cells
Long lasting expression and 
predictable chromosomal 
integration but small packaging 
ability
Adv Healthc Mater. Author manuscript; available in PMC 2018 February 13.
